European Association for Vision and Eye Research

September 30 - October 3, 2009
Portoroz, Slovenia

www.ever.be 21 CME credits
Dear Colleagues and Friends,

It gives me a great pleasure to welcome you to the 12th annual meeting of the European Association for Vision and Eye Research.

In keeping with the tradition of EVER, we have been able, thanks to your contributions, to put together under the guidance of the Programme Secretary a well balanced scientific programme in the form of special interest symposia, plenary lectures, courses and free papers. This programme continues to show a healthy mixture of high standard clinical and basic science and wide participation from the ophthalmic and vision science communities at large. We believe that it will provide an environment that will promote the interaction between clinicians and researchers and lead to new ideas and research directions. Further stimulating international collaborations and extending EVER international reputation are the scientific sessions put together by a number of major eye organizations, as well as this year’s joint meeting of KPro study group in collaboration with EVER.

This scientific programme will be accompanied by social events and you are all invited to the Welcome Reception on the evening of the 30th of September. I hope you will also join us at the EVER Farewell Dinner and Musical Entertainment.

The meeting concludes EVER’s triple visit to charming Portoroz. We are extremely grateful to our Slovenian colleagues under the steering of Marko Hawlina for securing an excellent venue and their valuable work in providing support for successful conferences.

This conference would not be possible without our sponsors, whose generosity in these difficult global economic times deserves our gratitude and appreciation.

I am looking forward to meeting you in Portoroz and all my thanks to all who have worked hard for the success of this meeting.

Yours sincerely

Charles RIVA
EVER President 2009
About EVER

EVER is a non-profit organisation. The aims of the association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

EVER is the largest European scientific organization which covers all subspecialties of ophthalmology and visual sciences. It provides an umbrella for other ophthalmological societies to meet during its annual congress. The official journal of EVER is Acta Ophthalmologica.

Membership

Membership is open to individuals of any nationality, engaging in or with an interest in ophthalmic and vision research, who meet the requirements established by the EVER Board. To become a member, a candidate should apply on the member’s module, on www.ever.be and fill in the name of an EVER member who will endorse their application. If candidates do not know a member who can endorse their application, they should write to the EVER office, which will take appropriate action. The candidate becomes a member upon recommendation by the EVER board and upon payment of the dues.

As an EVER member your benefits are:
- reduced fee for the annual meeting
- possibility of organizing Special Interest Symposia (SIS) during the annual meeting
- voting rights for the election of the Board Members
- free electronic subscription to Acta Ophthalmologica, the EVER journal
- travel grants for best paper in each section
- quarterly E-Newsletter

Elections

This year new representatives of the scientific sections Anatomy/Cell Biology, Molecular Biology / Genetics / Epidemiology and Vision Sciences / Electrophysiology / Physiological optics, will be elected through electronic voting. Voting 2009 will close on October 2, midnight. The result of the elections will be announced at the General Assembly on Saturday October 3, 2009. The scientific sections will hold their Business Meetings on Friday, October 2, 2009 from 12:35 - 13:35. Sandwiches and refreshments are provided. The agenda is available on page 41.

The following 2 sections will nominate at least 2 candidates for the succession of their representatives in the Board of EVER for elections in 2010: Neuro-ophthalmology/Strabismology/Paediatric Ophthalmology/History of Ophthalmology and Pathology/Oncology.

The statutes and by-laws are available on the website: www.ever.be » about » statutes

Section secretaries

<table>
<thead>
<tr>
<th>Section</th>
<th>Secretary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACB</td>
<td>Erich KNOP</td>
</tr>
<tr>
<td>COS</td>
<td>Jean-Jacques GICQUEL</td>
</tr>
<tr>
<td>G</td>
<td>Ingeborg STALMANS</td>
</tr>
<tr>
<td>IM</td>
<td>Carl HERBORT</td>
</tr>
<tr>
<td>LC</td>
<td>Jan-Olof KARLSSON</td>
</tr>
<tr>
<td>MBGE</td>
<td>Marzena GAJECKA</td>
</tr>
<tr>
<td>NSPH</td>
<td>Aki KAWASAKI</td>
</tr>
<tr>
<td>PBP</td>
<td>Neville OSBORNE</td>
</tr>
<tr>
<td>PO</td>
<td>Steffen HEEGAARD</td>
</tr>
<tr>
<td>RV</td>
<td>Elisabeth VAN AKEN</td>
</tr>
<tr>
<td>VEP</td>
<td>Werner SPILEERS</td>
</tr>
</tbody>
</table>

Programme Committee 2009

Programme secretary: Tero KIVELÄ

EVER 2009 programme
**Executive Committee**

- Charles Riva: President
- Bahram Bodaghi: Secretary General
- Pinar Aydin: Treasurer
- Tero Kivelä: Programme Secretary
- Graham Holder: President Elect
- Ralph Michael: Vice-President
- Marcela Votruba: Vice-President Elect
- Erich Knop: Vice-President Elect
- Harminder Dua: Past President

**Section chairs**

- Erich Knop: ACB
- Philippe Kestelyn: COS
- Thiery Zeyen: G
- Carl Herbolt: IM
- Alfred Wegener: LC
- Marcela Votruba: MBGE
- Lene Martin: NSPH
- Charlotta All-Ericsson: PO
- Leopold Schmetterer: PBP
- Constantin Pournaras: RV
- Graham Holder: VEP

**Regional representatives**

- Francesco Bandello: Italy
- Rimvydas Asoklis: East Europe
- Pinar Aydin: Greece, Balkan, Middle-East
- Marko Hawlina: Slovenia

**Local representative**

- Martine Jager: Advocacy
- Amanda Churchill: Advisor

**EVER office**

Kapucijnenvoer 33 3000 Leuven, Belgium marlene.verlaeckt@ever.be www.ever.be
Ever 2009 Programme

General Information

Venue

Ever 2009 will be held at the Bernardin Convention Center in Portoroz, Slovenia (visit the website on www.h-bernardin.si/en/congress_centre).

The scientific programme of the EVER congress starts on Wednesday, September 30 at 12:00 and concludes on Saturday, October 3 at 19:15.

Registration

Everyone attending the scientific sessions - whether or not an EVER member, invited speaker, accompanying person or presenter - must register and pay the registration fee.

The early registration deadline is September 1, 2009. On-site registration will be open from Wednesday, September 30, 11:00.

Please note that:

- being or becoming an EVER member - or having an abstract accepted - does not imply that you are registered
- if you register as a member-in-training, you need to prove your traineeship with a document signed by the Head of your Department
- registering as an accompanying person entitles you to attend the EVER social events, but not the scientific programme

Cancellation policy

Refunds – up to 75% of the advance registration fee will be granted for cancellation received in writing prior to September 20, 2009. Refunds will not be granted for later cancellations or no-shows.

Registration Fees after Sept. 1, 2009

<table>
<thead>
<tr>
<th></th>
<th>EUR</th>
<th>EUR</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVER member</td>
<td>350</td>
<td>275 *</td>
</tr>
<tr>
<td>SIS-invited speaker</td>
<td>350</td>
<td>275 *</td>
</tr>
<tr>
<td>Member-in-training</td>
<td>175</td>
<td>140 *</td>
</tr>
<tr>
<td>Non-member</td>
<td>570</td>
<td>460 *</td>
</tr>
<tr>
<td>Non-member-in-training</td>
<td>280</td>
<td>220 *</td>
</tr>
<tr>
<td>Course</td>
<td>50</td>
<td>30</td>
</tr>
<tr>
<td>Accompanying person</td>
<td>115</td>
<td>115 *</td>
</tr>
</tbody>
</table>

* Citizens of these listed countries only: Albania, Algeria, Armenia, Belarus, Bosnia and Herzegovina, Bulgaria, Congo, Croatia, Czech Republic, Egypt, Estonia, Georgia, Hungary, India, North Korea, Latvia, Libya, Lithuania, Macedonia, Moldova, Montenegro, Morocco, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Tunisia, Turkey, Ukraine. The list of countries will be updated annually and is based on the membership roster.

Website

The EVER website www.ever.be has a central role in the EVER organisation. At this website, you can:

- Obtain up-to-date information about the scientific programme and the EVER 2009 meeting and view the status (session, hour, place) of your presentation
- Pay on-line and obtain an overview of past payments
- Look for other EVER members
- Access general information about EVER
- Access Acta Ophthalmologica, the EVER journal
- Go to useful links, such as Concordia visu
- Express your vote for officers
- Print your CME certificate after the congress

Travel

Portoroz can be reached from Trieste airport (Italy) and from Ljubljana airport (Slovenia).

A congress shuttle service is available. Please book in advance through www.ever.be » housing and transfer.

- Congress transfer service* from Ljubljana and Trieste airport to Portoroz:
  - on arrival dates September 29-30,
  - on departure dates October 3-4.
- One-way shuttle bus transfer:
  Ljubljana airport to Portoroz: 35 EUR/person (90min.)
  Trieste airport to Portoroz: 30 EUR/person (90min.).
- Private transfer: individual service, private car or van transfer with English-speaking driver can be organised. Please contact: housing@cd-cc.si.

* Arrivals: The congress transfer service reserves the right to combine transfers for participants of the EVER congress with a maximum waiting time of 1 hour.

Departures: Please reconfirm your departure transfer at least 48 hrs prior to your departure at the housing desk.

Tourist Information

Slovenia is a country where the Alps meet the sea, a country of geographical diversity and natural beauty that you will be able to observe already on the way from Ljubljana airport to the town of Portoroz. Portoroz and Piran are two towns next to each other. The old tradition of Piran is matched with modern amenities in hotels that offer relaxing atmosphere and splendour.

The congress center is situated right in the middle of the two. The towns have many places offering pleasant atmosphere, with seafood restaurants and delicious wines.

Weather

September - October is an excellent time to visit Slovenia. It is the latter part of the warmest and driest time of the year.
Guidelines for speakers
Handling presentations at EVER 2009

EVER 2009 offers a high-performance network between all the different presentation rooms.

All presenters must read the following instructions:

The supported software used for the presentations is PowerPoint.

**Include your conflict of interest statement in the first slide.**

Oral presentations in the free paper sessions are limited to eight minutes, followed by four minutes of discussion. The session chairman will strictly enforce this schedule.

Rapid fire presentations should last no longer than 3-4 minutes with a 2 further minutes for questions from the audience. Do not use more than 2-3 PowerPoint slides for this presentation.

In the Speaker’s room Mediterranea II, a technician helps the speaker to transfer his or her presentation into the central congress network. When the transfer is complete, the technician performs a quick run of the presentation so the speaker can check whether the presentation runs correctly and all parts of the presentation are copied.

Inside each presentation hall, a technical assistant starts each presentation at the right time using one of the fixed computers connected to the central congress network.

We do not allow the use of personal laptops for presentations except in rare circumstances (for example, when the presentation has been created with movie creating software). If you bring your laptop to the congress, the technician will copy the files on your hard disk of the laptop into the central congress network, so the laptop will no longer be needed.

Of course, the easiest way is to bring your presentation on CD, DVD or memory stick. E-mailing or uploading of presentations will not be encouraged but can be used in special circumstances.

When a speaker wants to modify the presentation after it has been transferred to the central congress network, it can of course be updated to the new version upon request.

Centrally stored data will be deleted at the end of the congress so no copyright issues will arise.

**Best oral presentation prize**

A prize of 100 EUR will be awarded for the best oral presentation in each free paper session. The winners will be chosen by the moderators and will be announced in the General Assembly meeting on Saturday October 3.

Guidelines for posters

The poster exhibition takes place in Hall Europa C. Posters must be brought to the congress by the presenting author and should not be mailed in advance. The required dimensions are 95 cm (wide) by 180 cm (high). **NOTE: Portrait shape. Include your conflict of interest statement in your poster.**

Each poster is exhibited for one day only. All posters should be erected between 08:00 and 09:00 hrs on the day of presentation and must not be removed until 19:00 hrs. EVER is not responsible for any poster left behind at the end of the day.

You will find the number of your posterboard in one of the poster sessions of this programme book.

You are required to stand beside your poster during the poster session. On Thursday and Friday from 16:15 to 17:25, on Saturday from 15:20 - 16:30. During this time, moderators will be voting which poster should win the poster prize.

Some authors of posters, selected by the programme committee will be invited to give a brief rapid fire oral presentation.

**Poster prizes**

A poster prize of 200 EUR will be awarded for the best poster in each section. An additional VEP poster prize will be generously sponsored by the Alta Eficacia Tecnologia, SL, Spain. The winners will be chosen by the moderators and will be announced in the General Assembly meeting on Saturday October 3.

**Withdrawals**

First authors unable to attend EVER for reasons beyond their control, may request permission of the Programme Secretary to have another author present the paper. Alternatively, they should send a written notice of withdrawal to the EVER Office before September 20, 2009.

**No shows**

Please note that any first author, whose paper or poster, once it has been accepted, is not presented without a valid excuse, will be prohibited from presenting papers at EVER for the next two years.

**Liability**

The organisers cannot accept liability for personal accidents, loss of or damage to private property of participants and accompanying persons either during, or directly arising from the Meeting. Participants should make their own arrangements with respect to health and travel insurance.
Social programme

The social programme is open for all participants and registered accompanying persons:
- Wednesday 19:00, EVER Opening concert and welcome reception
- Saturday 20:00, EVER Farewell dinner

Coffee

Included in the registration fee are the coffee and soft drinks throughout the meeting from 09:45 until 11:00 and from 15:30 until 17:25 and the sandwiches and refreshments at the time of section business meetings on Friday 12:35-13:35.

Internet access

Wi-Fi internet access will be provided in Foyer next to hall Europa A. Please note the new location.

Photographs

It is strictly forbidden to take photographs or videos of the presentations in the lecture Halls.

Publication of the abstracts

The abstracts of the EVER 2009 congress will be published on-line in a special issue of Acta Ophthalmologica:
http://www3.interscience.wiley.com/journal/119816726/grouphome/home.html

Business meetings

- EVI General Assembly
  Thursday, 14:00 in Hall Aurora
- EVER BUSINESS MEETINGS OF THE SCIENTIFIC SECTIONS
  Friday, 12:35 - 13:35
  Europa A RV
  Europa B VEP/PBP
  Emerald I COS/ACB
  Emerald II LC/MBGE
  Mediterranea I G/IM
  Adria PO/NSHP
- EVER GENERAL ASSEMBLY
  Saturday, 16:40 in Hall Europa A
- OOG, Ophthalmic Oncology Group
  Saturday, 17:45 - 19:15, in Hall Adria

Ground floor

11th floor

Emerald I

Emerald II

Adria

Mediterranea II

Mediterranea I

Registration area

12th floor

Europa A

Europa B

Europa C

Posters

Refreshments

Exhibition area

Wi-Fi area

Hotel lobby

Speaker’s Room

Daphnia

Aurora

Foyer

EVER 2009 programme
EVER travel grants

We are pleased to announce that the following 11 members have received a travel grant of 400 EUR each from the EVER Sections:

- **ACB**
  Goran PETROVSKI - Hungary
  Clearance of dying cells in the retina-relevance to age-related macular degeneration

- **COS**
  Maria DE LA PAZ - Spain
  Ocular surface findings in patients with congenital aniridia

- **G**
  Amit TODANI - USA
  Measurement of IOP with radiowave telemetry

- **IM**
  Eva JAKOB - Germany
  Three years experience of Quantiferon® Gold testing

- **LC**
  Marcus KERNT - Germany
  Coenzyme Q10 prevents human lens epithelial cells from light-induced apoptotic cell-death by reducing oxidative stress and stabilizing BAX/Bcl-2 ratio

- **MBGE**
  Tine VAN BERGEN - Belgium
  Is inhibition of VEGF165 sufficient to inhibit scar formation after trabeculectomy?

- **NSPH**
  Raffaella ANGELI - Italy
  Preterm and at term children: morphological and functional analysis of optic nerve and visual pathway with OCT, HRT and pVEP

- **PO**
  Justyna DOPIERALA - UK
  Heterogeneity in uveal melanoma assessed by multiplex ligation-dependent probe amplification (MLPA)

- **PBP**
  Johanna VIIRI - Finland
  Cis-urocanic acid suppresses UV-B-induced interleukin-6 secretion and cytotoxicity in human corneal and conjunctival epithelial cells in vitro

- **RV**
  Efstratios MENDRINOS - Switzerland
  Internal limiting membrane surrounding idiopathic stage 4 macular hole contains bundles of actin microfilaments

- **VEP**
  Torsten STRASSER - Germany
  Development of a software for the exchange of electrophysiological data of vision with PACS systems based on DICOM

EVER listed countries travel grants

We are pleased to announce that the following 10 members from listed countries will receive a travel grant for the amount of 400 EUR:

- **Russia** - Andrey KACHANOV
  LASIK surgery for myopia in Chinese patients

- **Serbia** - Svetlana STANOJLOVIC
  Immune regulatory effect of rapamycin and cyclosporine A on experimental corneal allograft survival

- **Hungary** - Anita GARAS
  RTVue Fourier-domain OCT: reproducibility of RN-FLT and macular thickness measurements

- **Czech Republic** - Vladimir HOLAN
  Treatment of ocular surface injuries by the transfer of limbal and mesenchymal stem cells growing on nanofibrous scaffolds

- **Slovenia** - Spela STUNF
  Ultrastructure of anterior lens capsule in uveitic cataract

- **Poland** - Marzena GAJECKA
  Gene screening at the 13q32 keratoconus locus

- **India** - Sumita SETHI
  A Western blot analysis of P-glycoprotein in retinoblastoma

- **Latvia** - Liga RADECKA
  Wet AMD treatment with ranibizumab - structural and functional changes during treatment

- **Slovenia** - Natasa VIDOVIC
  The role of VEGF in intermediate uveitis patients

- **Lithuania** - Loresa KRIAUCIUNIENE
  Optico-anatomical changes of premature children eyes

TFOS grants

TFOS is pleased to announce that the following three researchers have received a travel award from the Tear Film and Ocular Surface Society for the three best abstracts submitted to EVER 2009 by young researchers in the cornea section:

- Jared AMENT: Boston, USA
- Stefano BARABINO: Genoa, Italy
- Antonia DEMESTICHA: Heraklion, Greece

Alta Eficacia Tecnología SL, Spain, travel grant

Alta Eficacia Tecnología SL is pleased to announce a travel grant of 400 EUR for the best paper in the VEP section

- Franziska RAUSCHER - UK
  Differential effects of ageing on foveal and peripheral colour vision
Wednesday
September 30, 2009
### Europa A  
**IM: Immune modulation in ocular disease: practice and controversies**  
**Course 1**  
Uwe PLEYER, Carl P HERBORT, Bahram BODAGHI, Piergiorgio NERI

The course presents an update on current practice of inflammation suppressive therapy indicate the indications, advantages and drawbacks of the different treatment modalities at our disposal including corticosteroids, immunomodulators, immunosuppressants and biological agents. In addition it addresses the (new) modalities at our disposal to optimally monitor the impact of inflammation suppressive therapy.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>Introduction by Uwe Pleyer</td>
<td></td>
</tr>
<tr>
<td>12:03</td>
<td>1211 Prevention of corneal graft rejection</td>
<td>PLEYER U–Berlin</td>
</tr>
<tr>
<td>12:12</td>
<td>1212 Principles of immunosuppression in uveitis</td>
<td>WILLERMAIN F, CASPERS L–Bruxelles</td>
</tr>
<tr>
<td>12:25</td>
<td>1213 The present role of corticosteroids in uveitis</td>
<td>KAHRALLAH M–Monastir</td>
</tr>
<tr>
<td>12:35</td>
<td>1214 Traditional immunosuppressants for uveitis</td>
<td>DE SMET M–Lausanne</td>
</tr>
<tr>
<td>12:50</td>
<td>1215 Interferon-alpha for uveitis</td>
<td>BODAGHI B, DICK AD–Paris, Bristol</td>
</tr>
<tr>
<td>13:00</td>
<td>1216 Immunosuppression in children (JIA)</td>
<td>BODAGHI B–Paris</td>
</tr>
<tr>
<td>13:10</td>
<td>1217 Infliximab (Remicade®) in uveitis: a review</td>
<td>ABU EL ASRAR A, NERI P, HERBORT CP–Riyadh, Torrette-Ancona, Lausanne</td>
</tr>
<tr>
<td>13:20</td>
<td>1218 Final results of European Remicade® RESCU study</td>
<td>DE SMET M–Lausanne</td>
</tr>
<tr>
<td>13:30</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>13:35</td>
<td>1219 Adalimumab (Humira®) therapy for uveitis</td>
<td>NERI P–Ancona</td>
</tr>
<tr>
<td>13:45</td>
<td>121a Mycophenolate mofetil in uveitis</td>
<td>NERI P–Ancona</td>
</tr>
<tr>
<td>13:55</td>
<td>121b Optimised monitoring of inflammation suppressive therapy (IST) in uveitis</td>
<td>HERBORT CP–Lausanne</td>
</tr>
<tr>
<td>14:07</td>
<td>121c The future in immunomodulation</td>
<td>DE SMET M–Lausanne</td>
</tr>
</tbody>
</table>

### Emerald I  
**PO: Well versed in statistics - Basics and writing skills**  
**Course 3**  
Tero KIVELÄ, Berfil DAMATO

Typical pitfalls, seldom addressed during basic courses in statistics, await the unwary scientist who is starting research in ophthalmology. These include proper ways of analysing data collected from both eyes of patients and proper ways of summarising and comparing visual acuities. Moreover, more senior scientists who regularly review manuscripts are aware of certain problems in presentation of data that should be trivial to solve, but which are surprisingly persistent. These comprise handling of follow-up data, recognising the often neglected yet common problem of multiple comparisons, how to communicate effect size, and how to cope with statistically non-significant results. This course will clarify the problems mentioned, based on examples from real life and from a practical rather than mathematical point of view. It will additionally provide guidelines for clear presentation of key aspects of research. After this course, your paper and statistics should be more likely to successfully pass the review process, and you should be in a better position as a reader and reviewer as well.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>1231 Pitfalls in statistics and how to avoid them - part 1</td>
<td>KIVELÄ T–Helsinki</td>
</tr>
<tr>
<td>12:35</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>12:50</td>
<td>1232 Tips and tricks for writing a manuscript</td>
<td>DAMATO B–Liverpool</td>
</tr>
<tr>
<td>13:25</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>13:40</td>
<td>1233 Pitfalls in statistics and how to avoid them - part 2</td>
<td>KIVELÄ T–Helsinki</td>
</tr>
</tbody>
</table>
### Mediterranean I  
**RV: EBO Review Course: From clinical analysis to final diagnosis: semiology is the key**  
Catherine CREUZOT

This course dedicated to residents for EBO training will highlight the interest of semiology in the analysis of clinical cases from various origins. Authors will focus their talk on the key role played by fundus analysis and the need of a good physiology and anatomy knowledge to understand the symptoms. The aim of this course is not to reach the diagnosis but rather to describe and to analyze the different items that are provided, ranging from visual field, angiogram, OCT, ERG, EOG, videotopography, aberrometry.

<table>
<thead>
<tr>
<th>Time</th>
<th>Course</th>
<th>Speaker &amp; Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>1251</td>
<td>Diabetic retinopathy</td>
</tr>
<tr>
<td></td>
<td>POURNARAS C J, MENDRINOS E-Geneva</td>
<td></td>
</tr>
<tr>
<td>12:20</td>
<td>1252</td>
<td>Pigmented lesions</td>
</tr>
<tr>
<td></td>
<td>DESJARDINS L-Paris</td>
<td></td>
</tr>
<tr>
<td>12:40</td>
<td>1253</td>
<td>Age related macular degeneration</td>
</tr>
<tr>
<td></td>
<td>VOIGT M-Paris</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>13:15</td>
<td>1254</td>
<td>Retinal dystrophies</td>
</tr>
<tr>
<td></td>
<td>HAWLINA M-Ljubljana</td>
<td></td>
</tr>
<tr>
<td>13:35</td>
<td>1255</td>
<td>What do I need to improve my glaucoma skills?</td>
</tr>
<tr>
<td></td>
<td>BRON AM-Dijon</td>
<td></td>
</tr>
<tr>
<td>13:55</td>
<td>1256</td>
<td>Refraction and refractive surgery</td>
</tr>
<tr>
<td></td>
<td>COCHENER B-Brest</td>
<td></td>
</tr>
</tbody>
</table>

### Europa B  
**COS: Corneal Infectious disease**  
Jean-Jacques GICQUEL, Harminder S DUA

<table>
<thead>
<tr>
<th>Time</th>
<th>Course</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td>1321</td>
<td>Corneal bacterial infections</td>
</tr>
<tr>
<td></td>
<td>CREUZOT C, BRON AM, BOURCIER T-Dijon, Strasbourg</td>
<td></td>
</tr>
<tr>
<td>14:50</td>
<td>1322</td>
<td>Infectious crystalline keratopathy</td>
</tr>
<tr>
<td></td>
<td>DUA HS-Nottingham</td>
<td></td>
</tr>
<tr>
<td>15:10</td>
<td>1323</td>
<td>Epidemiology of viral infections</td>
</tr>
<tr>
<td></td>
<td>LABETOUILLE M-Kremlin-Bicetre</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>1324</td>
<td>Herpes and zoster keratitis</td>
</tr>
<tr>
<td></td>
<td>BOURCIER T-Strasbourg</td>
<td></td>
</tr>
<tr>
<td>16:05</td>
<td>1325</td>
<td>Fungal infections</td>
</tr>
<tr>
<td></td>
<td>KESTELYN P-Gent</td>
<td></td>
</tr>
<tr>
<td>16:25</td>
<td>1326</td>
<td>Parasitic corneal infections</td>
</tr>
<tr>
<td></td>
<td>GICQUEL JJ-Poitiers</td>
<td></td>
</tr>
</tbody>
</table>
### Emerald II  RV: Retinal detachment

**Course 6** Catherine CREUZOT, Constantin POURNARAS

This course is dedicated to retinal detachment. Authors will consider successively the consequence of retinal detachment (RD) on retina with the results obtained from experimental models of RD. Then clinical cases of rhegmatogenous RD will be discussed with the various therapeutic options in pseudophakic and aphakic patients and particularly the indication of scleral buckling during primary vitrectomy. Some complicated cases occurring during uveitis or after ocular trauma will be presented. Finally the management of glaucoma after retinal surgery will be considered.

<table>
<thead>
<tr>
<th>Time</th>
<th>Code</th>
<th>Title</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td>1341</td>
<td>What is the consequence of retinal detachment on anatomy and function?</td>
<td>CREUZOT C–Dijon</td>
</tr>
<tr>
<td>14:50</td>
<td>1342</td>
<td>Retinal detachment in phakic patients</td>
<td>CHIQUET C–Grenoble</td>
</tr>
<tr>
<td>15:10</td>
<td>1343</td>
<td>Primary vitrectomy in retinal detachment: is scleral buckling still indicated?</td>
<td>POURNARAS CJ–Geneva</td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>1344</td>
<td>Retinal detachment after ocular trauma</td>
<td>JONAS JB–Mannheim</td>
</tr>
<tr>
<td>16:05</td>
<td>1345</td>
<td>Retinal detachment after uveitis</td>
<td>DE SMET M–Lauzanne</td>
</tr>
<tr>
<td>16:25</td>
<td>1346</td>
<td>Glaucoma and retina</td>
<td>BRON AM–Dijon</td>
</tr>
</tbody>
</table>

### Adria  PO: EBO Review Course: Ophthalmic Oncology

**Course 7** Laurence DESJARDINS

Objectives: at the conclusion of this course the attendee will be able to list the mains ophthalmic malignant tumours, their symptoms and usual diagnostic tools.

This course will focus on ocular, conjunctival, lid and orbital tumours. The first lecture will give an overview of the different intraocular and adnexal tumours with the clinical presentation and symptoms, pathology and main diagnostic tools. Clinical presentation, diagnosis and management of uveal melanoma will be covered as well as clinical presentation, diagnosis and treatment of retinoblastoma. The main conjunctival, lid and orbital tumours and their usual management will be described. Clinical cases will be presented as well as multiple choice questions. The goal of the course is to give the attendee some knowledge about the most frequent ophthalmic tumours with their clinical presentation and differential diagnosis with the ancillary tests and imaging tests to be performed for each of them.

<table>
<thead>
<tr>
<th>Time</th>
<th>Code</th>
<th>Title</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td>1361</td>
<td>Diagnosis of ophthalmic tumours</td>
<td>KIVELÄ T–Helsinki</td>
</tr>
<tr>
<td>14:45</td>
<td>1362</td>
<td>Management of uveal tumours</td>
<td>DAMATO B–Liverpool</td>
</tr>
<tr>
<td>15:00</td>
<td>1363</td>
<td>Management of retinal tumours</td>
<td>DESJARDINS L–Paris</td>
</tr>
<tr>
<td>15:15</td>
<td>1364</td>
<td>Management of conjunctival tumours</td>
<td>MIDENA E–Padova</td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>1365</td>
<td>Lid tumours</td>
<td>SEREGARD S–Stockholm</td>
</tr>
<tr>
<td>16:00</td>
<td>1366</td>
<td>Orbital tumours</td>
<td>PRAUSE JU–Copenhagen</td>
</tr>
</tbody>
</table>
Saturday, 16:40 - Hall Europa A

Remember to attend the General Assembly

... to witness the award ceremony
... to provide feedback to the organisers
... to meet the Board
... to express your opinion
... to hear the results of the elections
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Speaker(s)</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00 – 17:15</td>
<td>Welcome by the President EVER 2009</td>
<td>Europa A</td>
<td>Charles RIVA - President</td>
<td></td>
</tr>
<tr>
<td>17:20 – 18:00</td>
<td>Corneal surface regeneration: epithelial sheets to epithelial crypts</td>
<td>Europa A</td>
<td>Harminder DUA - Nottingham, UK</td>
<td>Introduction by Charles RIVA</td>
</tr>
<tr>
<td>18:25 – 19:00</td>
<td>From vitreal cell-encoated drug therapy to low-(brain-)pressure-glaucoma</td>
<td>Europa A</td>
<td>Jost JONAS - Mannheim, Germany</td>
<td>Introduction by Einar STEFANSSON</td>
</tr>
<tr>
<td>19:00 – 20:00</td>
<td>Opening concert given by Irena Preda (soprano) &amp; Marko Hallak (accordeon)</td>
<td>Europa C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00 – 21:30</td>
<td>EVER Welcome reception with musical entertainment</td>
<td>S. Bernardin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Europa A  **EURETINA Session: development of the OCT technology and its application**  
**Joint M.**  
**Rui BERNARDES**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>2111</td>
<td>Segmentation of FD-OCT images shows selective loss of inner retinal layers in patients with DM and no or early DR</td>
<td>VERBRAAK FD-Amsterdam</td>
<td></td>
</tr>
<tr>
<td>08:33</td>
<td>2112</td>
<td>Assessing macular edema- prognostic parameters by OCT</td>
<td>DE SMET M-Lauzanne</td>
<td></td>
</tr>
<tr>
<td>08:51</td>
<td>2113</td>
<td>Cirrus HD OCT algorithms for macula and retinal nerve fiber analysis</td>
<td>HORNE M-Dublin, CA</td>
<td></td>
</tr>
<tr>
<td>09:09</td>
<td>2114</td>
<td>High-definition Fourier domain OCT: non-invasive assessment of BRB changes</td>
<td>BERNARDES R, SANTOS T, CUNHA-VAZ J-Coimbra</td>
<td></td>
</tr>
<tr>
<td>09:27</td>
<td></td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Europa B  **PBP: Apoptosis and angiogenesis in retinal neurovascular degeneration: can it be prevented?**  
**SIS**  
**Paulo DE SOUZA-RAMALHO**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:33</td>
<td>2122</td>
<td>The role of HIF-1 alpha in apoptosis and proliferative retinopathy</td>
<td>FERNANDES R, BENTO C, MATAFOME P, SEIÇA R, PEREIRA P-Coimbra</td>
<td></td>
</tr>
<tr>
<td>08:51</td>
<td>2123</td>
<td>The effects of sub-conjunctival EPO administration on ERG and on the peripheral blood haematocrit in animal model (rabbit)</td>
<td>DELGADO E, RESENDE AP, SAO-BRAS B, DE SOUZA-RAMALHO P-Lisbon</td>
<td></td>
</tr>
<tr>
<td>09:27</td>
<td>2125</td>
<td>Intravitreal and plasmatic levels of erythropoietin after sub-conjunctival administration in rabbits</td>
<td>RESENDE AP, DELGADO E, SAO-BRAS B, DE SOUZA-RAMALHO P-Lisbon</td>
<td></td>
</tr>
</tbody>
</table>

Emerald I  **ACB: New concepts for tissue reconstruction in RPE**  
**SIS**  
**Hannu UUSITALO, Kai KAARNIRANTA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>2131</td>
<td>The clinical potential of RPE cells in retinal repair</td>
<td>DA CRUZ L-London</td>
<td></td>
</tr>
<tr>
<td>08:45</td>
<td>2132</td>
<td>Stem cell applications for retinal pigment epithelial cell defects</td>
<td>SKOTTMAN H-Tampere</td>
<td></td>
</tr>
<tr>
<td>09:15</td>
<td>2133</td>
<td>Biomaterials for RPE tissue engineering and cell microencapsulation</td>
<td>URTTI A-Kuopio</td>
<td></td>
</tr>
</tbody>
</table>

Adria  **NSPH: Visual function following prematurity and/or very low birth weight - What can we learn from the past for the future?**  
**SIS**  
**Lene MARTIN**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>2161</td>
<td>Visual and cognitive function in adolescents born with very low birth weight - a 15-year follow-up</td>
<td>HELLGREN K-Stockholm</td>
<td></td>
</tr>
<tr>
<td>08:33</td>
<td>2162</td>
<td>Ocular motor development in normal and premature children</td>
<td>YGGE J-Stockholm</td>
<td></td>
</tr>
<tr>
<td>08:51</td>
<td>2163</td>
<td>Eye alignment in low birth weight and/or prematurity</td>
<td>ARING E-Göteborg</td>
<td></td>
</tr>
<tr>
<td>09:09</td>
<td>2164</td>
<td>Visual impairment in children born before 25 gestational weeks - boys are more vulnerable than girls</td>
<td>JACOBSON L-Stockholm</td>
<td></td>
</tr>
<tr>
<td>09:27</td>
<td>2165</td>
<td>Update on risk factors and future perspectives for preterm infants</td>
<td>HELLSTRÖM A-Göteborg</td>
<td></td>
</tr>
</tbody>
</table>
### Emerald II

**FP**

<table>
<thead>
<tr>
<th>Time</th>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>2141</td>
<td>Regulation of retinal ganglion cell gene expression by bHLH transcription factors in the developing and ischemic retinas&lt;br&gt;MATTER JM, CHIODINI F, DELAFOSSE L, MATTER-SADZINSKI L, POURNARAS CJ–Geneva</td>
</tr>
<tr>
<td>08:39</td>
<td>2143</td>
<td>Role of inflammation-related gene polymorphisms in branch retinal vein occlusion&lt;br&gt;WEGER M, STEINBRUGGER I, RENNER W, MAIER R, WEDRICH A, SCHMUT O, HAAS A–Graz</td>
</tr>
<tr>
<td>08:51</td>
<td>2144</td>
<td>Morphological and functional characteristics of the hyperautofluorescent parafoveal ring in retinitis pigmentosa&lt;br&gt;LENNASI E, POPOVIC P, PEROVSEK D, HAWLIN M–Ljubljana</td>
</tr>
<tr>
<td>09:03</td>
<td>2145</td>
<td>Gene therapy mediates cone rescue and rejuvenation in the R91W mutant form of Rpe65-deficiency mice&lt;br&gt;ARSENIJEVIC Y, CRIPPA S, PIGNAT V, SAMARDZIJA M, KOSTIC C–Lausanne, Zurich</td>
</tr>
<tr>
<td>09:09</td>
<td>2146</td>
<td>Importance of electroretinogram in bull’s eye maculopathy&lt;br&gt;HALFELD FURTADO DE MENDONCA R, KOK F, ROSEMBERG S, YUKIHIKO TAKAHASHI W–São Paulo</td>
</tr>
<tr>
<td>09:15</td>
<td>2147</td>
<td>LOC387715/ARMS2 studies – gene sequencing as a procedure of choice&lt;br&gt;WYLEGALA E, TEPER S, NOWINSKA A–Katowice</td>
</tr>
<tr>
<td>09:21</td>
<td>2148</td>
<td>Hunter’s syndrome and buphthalmos in a girl: an unusual ophthalmic association&lt;br&gt;SETHI S, BHARTIYA S, MEHTA M, CHANDRA M, GHOSE S–Delhi</td>
</tr>
</tbody>
</table>

### Mediterranea I

**G: Ocular Rigidity: Biomechanical aspects and clinical applications**

**SIS** Konstantin KOTLIAR

<table>
<thead>
<tr>
<th>Time</th>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>2151</td>
<td>Why do we need a biomechanical approach to the ocular rigidity concept?&lt;br&gt;KOTLIAR KE, KOSHITS IN, BAUER S, LÖHMANN CP, LANZL IM–Munich, St. Petersburg</td>
</tr>
<tr>
<td>08:30</td>
<td>2152</td>
<td>Biomechanical models for clinical data analysis of pressure-volume relationship in the human eye&lt;br&gt;BAUER S, KOTLIAR KE, STEIN A, VORONKOVA E–St. Petersburg, Munich, Moscow</td>
</tr>
<tr>
<td>08:45</td>
<td>2153</td>
<td>Ocular rigidity in living human eyes in health and disease&lt;br&gt;PALLIKARIS IG–Heraklion</td>
</tr>
<tr>
<td>09:00</td>
<td>2154</td>
<td>Ocular rigidity and ocular response analyzer&lt;br&gt;IODMINA E, ARUTUNYAN L, IGNATIEVA N, DANILOV N–Moscow</td>
</tr>
<tr>
<td>09:15</td>
<td>2155</td>
<td>Evidence for altered ocular rigidity in glaucoma&lt;br&gt;SCHMETTERER L, GARHOFER G–Vienna</td>
</tr>
<tr>
<td>09:30</td>
<td>2156</td>
<td>Ocular pulse amplitude under pressure: what happens to OPA in glaucoma before and after surgery?&lt;br&gt;STALMANS I, ZEYEN T, BREUSEGEM C–Leuven</td>
</tr>
</tbody>
</table>

### Daphnia

**COS: KPro cornea**

**FP** Christopher LIU

<table>
<thead>
<tr>
<th>Time</th>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>2171</td>
<td>A new tissue-polymer hybrid drug delivery system for artificial corneas&lt;br&gt;SHEN T, BARRETT R, GARTY S, KANAYAMA S–Seattle</td>
</tr>
<tr>
<td>08:27</td>
<td>2172</td>
<td>Evaluation of anterior chamber depth in aphakic and pseudophakic patients with Boston type 1 keratoprosthesis&lt;br&gt;DE LA CRUZ J, GUPTA S, ELDERKIN S, GARCIA J–Chicago, New York</td>
</tr>
<tr>
<td>08:39</td>
<td>2173</td>
<td>Retinal detachments after Boston keratoprosthesis: incidence, predisposing factors and outcomes of repair&lt;br&gt;JARDELEZA MS, DOHLMAN CH, YOUNG L–Boston</td>
</tr>
<tr>
<td>08:45</td>
<td>2174</td>
<td>Prospective evaluation of the Boston keratoprosthesis&lt;br&gt;AMENT JD, PINEDA R, TILAHUN Y, BEHLAU I, DOHLMAN CH–Boston, Addis Ababa</td>
</tr>
<tr>
<td>08:51</td>
<td>2175</td>
<td>Cost-effectiveness of the Boston keratoprosthesis&lt;br&gt;AMENT JD, STRYJEWSKI TP, DOHLMAN CH–Boston</td>
</tr>
</tbody>
</table>

### Keynote Lecture 1

**Pathogen interactions in the pathogenesis of endophthalmitis**

**10:00 – 10:45**

**Europa A** Michael GILMORE - Boston, USA

Introduction by Constantin POURNARAS
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Room</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>RV</td>
<td>Europa A</td>
<td>Visualization techniques of the retina</td>
<td>Frank VERBRAAK, Carl ARNDT</td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td>Macular thickness alterations after cataract surgery determined by optical coherence tomography</td>
<td>ELEFTHERIDOU M, FRAGISKOU S, KYMIONIS G, PAPADAKI T, PANTELEONIDIS V, PALLIKARIS IG, TSILIMBARIS M-Heraklion</td>
</tr>
<tr>
<td>11:12</td>
<td></td>
<td></td>
<td>Slitlamp integrated OCT, what you can see, is what you can scan</td>
<td>VERBRAAK FD, STEHOUWER M, DEVRIES H, VANLEEUIJEN TG-Amsterdam, Capelle a/d IJssel</td>
</tr>
<tr>
<td>11:24</td>
<td></td>
<td></td>
<td>Scanning beyond the limits of standard OCT: OCT scans of the peripheral retina and the anterior chamber angle with a slitlamp integrated FD-OCT system</td>
<td>STEHOUWER M, VERBRAAK FD, DE VRIES H, VAN LEEUWEN TG-Amsterdam, Capelle a/d IJssel</td>
</tr>
<tr>
<td>11:36</td>
<td></td>
<td></td>
<td>Screening for retinal detachment using a wide field scanning laser ophthalmoscope</td>
<td>BONNAY G, NGUYEN F, NAHOLZ N, BOUSQUET E, DUCASSE A, ARNDT C-Reims, Montpellier</td>
</tr>
<tr>
<td>11:48</td>
<td></td>
<td></td>
<td>Optical coherence tomography and biomicroscopical analysis in macular holes</td>
<td>FRUSCHELLI M, MOTOLESE I, MOTOLESE PA, FREZZOTTI P, MOTOLESE E-Siena, Grosseto</td>
</tr>
<tr>
<td></td>
<td>PBP</td>
<td>Europa B</td>
<td>Physiology-Biochemistry-Pharmacology 1</td>
<td>Paul BISHOP, Leopold SCHMETTERER</td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td>Does internal longitudinal microstructure of retinal veins change with age in medically healthy persons?</td>
<td>KOTLIAR KE, KHAROUBI A, SCHMIDT-TRUCKSAß A, HALLE M, LANZLA IM-Munich, Basel</td>
</tr>
<tr>
<td>11:24</td>
<td></td>
<td></td>
<td>Lomoxicam pharmacokinetics in the vitreous humor of albino rabbits</td>
<td>TSIKA C, TSOURDOU A, TSILIMBARIS M, PALLIKARIS IG-Heraklion</td>
</tr>
<tr>
<td>11:36</td>
<td></td>
<td></td>
<td>Subconjunctival injection of bevacizumab (Avastin®) for corneal neovascularization</td>
<td>DE LA PAZ MF, DE SOUSA F, PONCE C, ALVAREZ J, BARRAQUER Ri-Barcelona</td>
</tr>
<tr>
<td>11:48</td>
<td></td>
<td></td>
<td>Activity of corneal nociceptive nerve fibers during allergic challenge of the ocular surface</td>
<td>GALLAR J, ACOSTA MC, LUNA C, BELMÔNTE C-Santo Joan d’Alacant</td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td>Cytochrome C oxidase expression in retinal rod outer segment disks</td>
<td>BARABINO S, PANFOLI I, CALZIA D, ROLANDO M, MORELLI A-Genoa</td>
</tr>
<tr>
<td>12:06</td>
<td></td>
<td></td>
<td>Vasopressin receptors in ocular tissues and their impact on ocular hydrodynamics</td>
<td>BOGNER B, TOCKNER B, RUNGE CW, STROHMAIER C, GRABNER G, REITSAMER HA-Salzburg</td>
</tr>
<tr>
<td></td>
<td>ACB</td>
<td>Emerald I</td>
<td>Ocular anatomy and cell biology</td>
<td>Nadja KNOP, Yvan ARSENJEVIC</td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td>The neuromuscular junction microenvironment in extraocular and limb muscles</td>
<td>PEDROSA DOMELLOF F, BRÄNNSTRÖM T, ANDERSEN PM, MARKLUND SL, LIU J-Umeå</td>
</tr>
<tr>
<td>11:12</td>
<td></td>
<td></td>
<td>Keratinisation status and cytokeratins of the human Meibomian gland epithelium</td>
<td>KNOP E, LUDESCHER M, KNOP N-Berlin, Hannover</td>
</tr>
<tr>
<td>11:24</td>
<td></td>
<td></td>
<td>In search for correlation among markers for limbal stem cells niche</td>
<td>CURCIO C, CALIENNIO R, LANZINI M, IZZI M, MARIOTI M, COLESANI M, NUBILE M-Ciampi</td>
</tr>
<tr>
<td>11:36</td>
<td></td>
<td></td>
<td>Chromosomal number aberrations and transformation in adult mouse retinal stem cells in vitro</td>
<td>DJOJOSUBROTO M, BOLLOTTE F, WIRAPATI F, RADIKE F, STAMENKOVIC I, ARSENJEVIC Y-Lausanne</td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td>The Bmi1 polycomb gene as a target for therapies against retinal degeneration</td>
<td>ARSENJEVIC Y, VAN LOHUIZEN M, ZENCAK D-Lausanne, Amsterdam</td>
</tr>
<tr>
<td></td>
<td>MBGE</td>
<td>Emerald II</td>
<td>Genotypes and phenotypes</td>
<td>Jochen GRAW, Marzena GAJECKA</td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td>Splicing defect in Calpain12 cDNA of a recessive cataract mutation in rats (cat)</td>
<td>GRAW J-Neuherberg</td>
</tr>
<tr>
<td>11:24</td>
<td></td>
<td></td>
<td>Phenotype-genotype relationship of TGFβ1 corneal dystrophies among Polish families</td>
<td>NOWINSKA A, WYLEGALA E-Katowice</td>
</tr>
<tr>
<td>11:36</td>
<td></td>
<td></td>
<td>Gene screening at the 13q32 keratoconus locus</td>
<td>GAJECKA M-Poznan</td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td>Analysis of SERPING1 and its association with age-related macular degeneration</td>
<td>CARTER JG, CHURCHILL AJ-Bristol</td>
</tr>
</tbody>
</table>
## Mediterranean I

**G: Monitoring glaucoma patients: visual field and imaging**  
11:00 – 12:30

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>2251</td>
<td>Until what age should glaucoma be monitored and/or treated? A novel index that facilitates clinical decision making</td>
<td>JANSONIUS N, WESSELINK C, STOUTENBEEK R–Groningen</td>
</tr>
<tr>
<td>11:12</td>
<td>2252</td>
<td>Relationship between standard automated perimetry and high-resolution optical coherence tomography in glaucoma patients</td>
<td>CALVO PEREZ P, FERRERAS A, ABADIA B, PABLO LE, PAJARIN AB, LARROSA JM–Zaragoza</td>
</tr>
<tr>
<td>11:24</td>
<td>2253</td>
<td>RTVue Fourier-domain OCT: reproducibility of RNFLT and macular thickness measurements</td>
<td>GARAS A, KOTHY P, HOLLO G–Budapest</td>
</tr>
<tr>
<td>11:36</td>
<td>2254</td>
<td>Retinal nerve fiber layer thickness and central corneal thickness in ocular hypertensive patients and healthy subjects</td>
<td>BRON AM, MUSELIER A, REULAND J–C-Dijon</td>
</tr>
<tr>
<td>11:48</td>
<td>2255</td>
<td>Rarebit visual field follow-up in pediatric glaucoma</td>
<td>MARTIN L, LUNDVALL NILSSON A–Stockholm</td>
</tr>
<tr>
<td>11:54</td>
<td>2256</td>
<td>The retinal nerve fiber layer and the optic nerve head morphology after glaucoma surgery</td>
<td>GRACNER T, PAHOR D–Maribor</td>
</tr>
</tbody>
</table>

## Adria

**NSPH: Neuro-ophthalmology and Immunology**  
11:00 – 12:30

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>2261</td>
<td>Toxic effect of vigabatrin on retinal nerve fiber layer</td>
<td>MIDELFART A, MOSENG L, SAETER M–Trondheim</td>
</tr>
<tr>
<td>11:24</td>
<td>2263</td>
<td>Studying electrophysiological characteristics in children with congenital sensory nystagmus- case presentations</td>
<td>BRECCELI J, STIRN-KRANJIC B–Ljubljana</td>
</tr>
<tr>
<td>11:36</td>
<td>2264</td>
<td>Zone-I retinopathy of prematurity, progression and scheduling of treatment</td>
<td>AKKOYUN I, OTO S, YILMAZ G, TARCAN A, AKOVA AY–Ankara</td>
</tr>
<tr>
<td>11:42</td>
<td>2265</td>
<td>A new technique of anterior TAP enhances the positivity of CMV by PCR in hypertensives anterior uveitis</td>
<td>KOCH P, LIESNARD C, JUDICE L, MAKOUL D, WILLERMAIN F, CASPERS L–Brussels</td>
</tr>
</tbody>
</table>

## Daphnia

**COS: Keratoconus and corneal grafting**  
11:00 – 12:30

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>2271</td>
<td>Can the corneal endothelium of the pig proliferate in vivo?</td>
<td>NICHOLLS S, BAILEY M, MITCHARD L, DICK AD–Bristol</td>
</tr>
<tr>
<td>11:24</td>
<td>2273</td>
<td>A new storage medium for pre-cut donor tissue for DSAEK in eye bank</td>
<td>POCOBELLI A, AMATO D, DUCOLI P–Rome</td>
</tr>
<tr>
<td>11:36</td>
<td>2274</td>
<td>Effect of corneal collagen crosslinking on corneal sensitivity, tear function and innervation: a clinical and confocal microscopic study</td>
<td>KONTADAKIS GA, KYMONIS G, PORTALIOU D, DIKONIS V, PALIKARIS IG–Heraklion</td>
</tr>
<tr>
<td>11:48</td>
<td>2275</td>
<td>Results of amniotic membrane transplantation with diathermocoagulation for corneal hydrops secondary to keratoconus</td>
<td>MILKA M, WYLEGALA E–Katowice</td>
</tr>
<tr>
<td>12:00</td>
<td>2276</td>
<td>DSAEK grafted corneas remain clear with low endothelial cell counts</td>
<td>OLESEN H–Copenhagen</td>
</tr>
<tr>
<td>12:12</td>
<td>2277</td>
<td>Comparison of deep anterior lamellar keratoplasty results in different TGFβi corneal dystrophies.</td>
<td>NOWINSKA A, WYLEGALA E–Katowice</td>
</tr>
</tbody>
</table>
Submit your next paper to the EVER Journal, Acta Ophthalmologica
## Ocular surface, what's new in 2009?

### Alain BRON

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:35</td>
<td>Introduction</td>
</tr>
<tr>
<td>12:41</td>
<td>Prophylaxis in ocular surgery</td>
</tr>
<tr>
<td></td>
<td>BRON AM-Dijon</td>
</tr>
<tr>
<td>12:53</td>
<td>Meibomian gland dysfunction: management and treatment</td>
</tr>
<tr>
<td></td>
<td>DOAN S-Paris</td>
</tr>
<tr>
<td>13:05</td>
<td>A new treatment for Meibomian gland dysfunction</td>
</tr>
<tr>
<td></td>
<td>PURSLOW C-Birmingham</td>
</tr>
<tr>
<td>13:17</td>
<td>The prophylactic and therapeutic efficacy of a new eye drop for the</td>
</tr>
<tr>
<td></td>
<td>treatment of murine dry eye induced by intelligently controlled</td>
</tr>
<tr>
<td></td>
<td>environmental system</td>
</tr>
<tr>
<td></td>
<td>ZHANG X-WenZhou</td>
</tr>
<tr>
<td>13:29</td>
<td>Conclusions</td>
</tr>
<tr>
<td>13:35</td>
<td>End of session</td>
</tr>
</tbody>
</table>

12:35 – 13:35
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45</td>
<td>Europa A</td>
<td><strong>RV:</strong> In vivo imaging of cellular dynamics in the eye</td>
<td>Michel PAQUES</td>
</tr>
<tr>
<td>13:45</td>
<td>2311</td>
<td>In vivo imaging of microglial cell trafficking</td>
<td>PAQUES M, SIMONUTTI M, SAHEL J–Paris</td>
</tr>
<tr>
<td>14:15</td>
<td>2312</td>
<td>In vivo imaging of retinal inflammation in experimental autoimmune uveoretinitis</td>
<td>XU H–Aberdeen</td>
</tr>
<tr>
<td>14:45</td>
<td>2313</td>
<td>In vivo confocal microscopic evaluation of inflammatory changes in the ocular surface</td>
<td>LABBE A, BAUDOUIN C–Paris</td>
</tr>
<tr>
<td>13:45</td>
<td>Europa B</td>
<td><strong>PBP:</strong> Nitric oxide in the healthy and unhealthy eye</td>
<td>Leopold SCHMETTERER, Neville OSBORNE</td>
</tr>
<tr>
<td>13:45</td>
<td>2321</td>
<td>Role of NO in retinal vascular disease</td>
<td>SCHMETTERER L–Vienna</td>
</tr>
<tr>
<td>14:03</td>
<td>2322</td>
<td>Introduction on the multifaceted roles of nitric oxide in the retina</td>
<td>OSBORNE NN–Oxford</td>
</tr>
<tr>
<td>14:21</td>
<td>2323</td>
<td>Interventions via the NO system and tachyphylaxia</td>
<td>PRASANNA G–San Diego</td>
</tr>
<tr>
<td>14:39</td>
<td>2324</td>
<td>Nitric oxide and inflammation</td>
<td>DICK AD–Bristol</td>
</tr>
<tr>
<td>14:57</td>
<td>2325</td>
<td>Nitric oxide and cGMP protect the retina from ischemia and mediate somatostatin’s neuroprotective effects</td>
<td>THERMOS K, KIAGIADAKI F, MASTRODIMOU N–Heraklion</td>
</tr>
<tr>
<td>13:45</td>
<td>Emerald I</td>
<td><strong>ACB:</strong> The Meibomian gland - revisited: anatomy, physiology and contribution to ocular surface disease</td>
<td>Erich KNOP, Nadja KNOP, Anthony J. BRON</td>
</tr>
<tr>
<td>13:45</td>
<td>2331</td>
<td>Anatomy of the Meibomian gland</td>
<td>KNOP E, KNOP N–Berlin, Hannover</td>
</tr>
<tr>
<td>14:03</td>
<td>2332</td>
<td>Physiological impact of the Meibomian gland on ocular surface integrity</td>
<td>BRON AJ–Oxford</td>
</tr>
<tr>
<td>14:21</td>
<td>2333</td>
<td>Keratinisation of the Meibomian gland as an important factor in Meibomian gland dysfunction (MGD)</td>
<td>KNOP N, KNOP E–Hannover, Berlin</td>
</tr>
<tr>
<td>14:39</td>
<td>2334</td>
<td>New insights into Meibomian gland function from gene expression experiments</td>
<td>SCHIRRA F, SEITZ B–Homburg/Saar</td>
</tr>
<tr>
<td>14:57</td>
<td>2335</td>
<td>Pathological alterations in Meibomian gland dysfunction as an important factor in ocular surface disease</td>
<td>BARABINO S–Genoa</td>
</tr>
<tr>
<td>13:45</td>
<td>Emerald II</td>
<td><strong>MBGE:</strong> Genes and markers in AMD</td>
<td>Marcela VOTRUBA, Albert EDWARDS</td>
</tr>
<tr>
<td>13:45</td>
<td>2341</td>
<td>The role of SERPING1 in age related macular degeneration</td>
<td>LOTERY AJ, ENNIS S, GIBSON J, CREE A, HARRIS C, MORGAN P–Southampton, Cardiff</td>
</tr>
<tr>
<td>14:00</td>
<td>2342</td>
<td>CFH, C3 and ARMS2 are significant risk loci for age-related macular degeneration but not for late stage disease progression</td>
<td>SCHOLL HPN–Bonn</td>
</tr>
<tr>
<td>14:15</td>
<td>2343</td>
<td>Genetic influences on biomarkers in AMD</td>
<td>CHONG V–Oxford</td>
</tr>
<tr>
<td>14:30</td>
<td>2344</td>
<td>Functional genomics of systemic complement activation in AMD</td>
<td>EDWARDS AO–Rochester</td>
</tr>
<tr>
<td>14:45</td>
<td>2345</td>
<td>Can diet reduce the genetic risk of AMD?</td>
<td>KLAVER C–Rotterdam</td>
</tr>
<tr>
<td>15:00</td>
<td>2346</td>
<td>Individualised risk in AMD</td>
<td>MACKAY D–Nedlands</td>
</tr>
</tbody>
</table>
### Mediterranean I

**G: Blood flow in glaucoma - new horizons**

**SIS**

13:45 – 15:15

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45</td>
<td>2351 Ocular blood flow autoregulation and the clinical implications of its alteration&lt;br&gt;<strong>GARHOFER G</strong>–Vienna</td>
</tr>
<tr>
<td>14:07</td>
<td>2352 Most readily usable methods to measure ocular blood flow&lt;br&gt;<strong>GUGLETA K</strong>–Basel</td>
</tr>
<tr>
<td>14:29</td>
<td>2353 Disease mechanisms leading to impaired blood flow in glaucoma&lt;br&gt;<strong>GERGHHEL D</strong>–Birmingham</td>
</tr>
<tr>
<td>14:51</td>
<td>2354 Impact of medication on ocular blood flow&lt;br&gt;<strong>SCHMETTERER L</strong>–Vienna</td>
</tr>
</tbody>
</table>

### Adrienne

**NSPH: Management in pediatric ophthalmology**

**SIS**

13:45 – 15:15

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45</td>
<td>2361 Recent developments of glaucoma in children&lt;br&gt;<strong>NISCHAL KK</strong>–London</td>
</tr>
<tr>
<td>14:03</td>
<td>2362 Recent developments of dry eye in children&lt;br&gt;<strong>BREMOND-GIGNAC D</strong>–Amiens</td>
</tr>
<tr>
<td>14:21</td>
<td>2363 Management of neuro-ophthalmology cases in children&lt;br&gt;<strong>MILAZZO S</strong>–Amiens</td>
</tr>
<tr>
<td>14:39</td>
<td>2364 Recent developments of ocular allergy in children&lt;br&gt;<strong>CHIAMBARETTA F</strong>–Clermont Ferrand</td>
</tr>
<tr>
<td>14:57</td>
<td>2365 Recent developments in retinopathy of prematurity&lt;br&gt;<strong>MORTEMOUSQUE B</strong>–Bordeaux</td>
</tr>
</tbody>
</table>

### Daphnia

**CONCORDIA: Designing effective courses for European residents and teachers in ophthalmology**

**Workshop**

Marko **HAWLINA**, Werner **SPILEERS**, Charles **RIVA**

13:45 – 15:15

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45</td>
<td>2371 Concordia pro visu: initiative, purpose and developments&lt;br&gt;<strong>KIVELÄ T</strong>–Helsinki</td>
</tr>
<tr>
<td>14:00</td>
<td>2372 EBO, ENET and accredited courses&lt;br&gt;<strong>TASSIGNON MJ</strong>–Antwerp</td>
</tr>
<tr>
<td>14:15</td>
<td>2373 EUPO courses&lt;br&gt;<strong>SPILEERS W</strong>–Leuven</td>
</tr>
<tr>
<td>14:30</td>
<td>2374 SOE and its role in Concordia&lt;br&gt;<strong>SEREGARD S</strong>–Stockholm</td>
</tr>
<tr>
<td>14:45</td>
<td>2375 EVER and emphasis of research in teaching&lt;br&gt;<strong>RIVA CE</strong>–Bologna</td>
</tr>
<tr>
<td>15:00</td>
<td>2376 Current methods of teaching ocular microsurgery&lt;br&gt;<strong>ZAGORSKI ZF</strong>–Lublin</td>
</tr>
</tbody>
</table>

### EVI Award Lecture

**Common or individual molecular mechanisms underlying different forms of retinal degeneration**

EVA awardee 2009: Valeria **MARIGO PhD** - Modena, Italy

Introduction by Eberhard **ZRENNER**

### Poster session 1

**Anatomy/Cell Biology - Glaucoma - Molecular Biology/Genetics/Epidemiology - Physiology/ Biochemistry/Pharmacology**

### EVER 2009 programme

#### THURSDAY

##### SECOND AFTERNOON SESSION

**Europa A**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>RV:</td>
<td><strong>Alternative applications for anti-VEGF therapy and PDT</strong></td>
<td>17:30 – 19:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hansjürgen T. AGOSTINI, Jean-Jacques DE LAEY</td>
<td></td>
</tr>
<tr>
<td>17:42</td>
<td>2412</td>
<td>Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses</td>
<td>MONTERO MORENO JA, RUIZ-MORENO JM–Valladolid, Albacete</td>
</tr>
<tr>
<td>17:30</td>
<td>2413</td>
<td>VEGF is reduced in breast milk after intravitreal injection of bevacizumab</td>
<td>EHLKEN C, STAHL A, AGOSTINI HT–Freiburg</td>
</tr>
<tr>
<td>18:06</td>
<td>2414</td>
<td>Inflammatory factors in experimental retinal vein occlusion</td>
<td>REHAK M, HOLLBORN M, IANDIEV I, PANNICKE T, WIEDEMANN P, BRINGMANN A–Leipzig</td>
</tr>
<tr>
<td>18:18</td>
<td>2415</td>
<td>Low dose verteporfin (1.5mg/m²) in chronic idiopathic central serous chorioretinopathy</td>
<td>SETROUK E, GARCIA T, DUCASSE A, ARNDT C–Reims</td>
</tr>
<tr>
<td>18:30</td>
<td>2416</td>
<td>Apoptotic activity of intravitreal bevacizumab on rabbit retina</td>
<td>TURKCU MF, ALP MN, TURKCU G, KULACOGLU S, KURAL G–Ankara</td>
</tr>
<tr>
<td>18:36</td>
<td>2417</td>
<td>Intravitreal bevacizumab as primary local treatment for choroidal neovascularization secondary to uveitis</td>
<td>JULIAN K, FARDEAU C, TERRADA C, FRANCAIS C, LEHOANG P, BODAGHI B–Paris</td>
</tr>
<tr>
<td>18:42</td>
<td>2418</td>
<td>Photodynamic therapy for symptomatic circumscribed choroidal hemangioma</td>
<td>MAYER CF, WACKERNAGEL W, LACKNER EM, SCHNEIDER MR, HAAS A, WEGER M, LANGMANN G–Graz</td>
</tr>
</tbody>
</table>

**Europa B**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>PBP:</td>
<td><strong>Physiology-Biochemistry-Pharmacology 2</strong></td>
<td>17:30 – 19:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neville OSBORNE, Herbert REITSAMER</td>
<td></td>
</tr>
<tr>
<td>17:42</td>
<td>2422</td>
<td>Microstructural alterations of the retinal arterial blood column along the vessel axis in healthy volunteers with age</td>
<td>LANZL IM, KHAROUBI A, SCHMIDT-TRUCKSÄSS A, HALLE M, KOTLIAR KE–Munich, Basel</td>
</tr>
<tr>
<td>17:54</td>
<td>2423</td>
<td>Effect of breathing a mixture of 92% O₂ + 8% CO₂ on flicker induced vasodilatation</td>
<td>LASTA M, PEMP B, GARHOFER G, SCHMETTERER L–Vienna</td>
</tr>
<tr>
<td>18:06</td>
<td>2424</td>
<td>Effects of moxaverine on ocular blood flow in patients with age-related macular degeneration, patients with primary open angle glaucoma and in healthy controls</td>
<td>PEMP B, GARHOFER G, LASTA M, SCHMIDL D, SCHMETTERER L–Vienna</td>
</tr>
<tr>
<td>18:18</td>
<td>2425</td>
<td>Effect of glaucoma and glaucoma risk factors on choroidal hemodynamics</td>
<td>ABOU SAMRA W, RIVA CE, POURNARAS CJ, EMARAH M–Mansoura, Sion, Geneva</td>
</tr>
<tr>
<td>18:30</td>
<td>2426</td>
<td>In vitro transcorneal and transscleral diffusion of radiolabeled compounds in human and rabbit cornea and in human, monkey, dog, and rabbit sclera</td>
<td>STRUBLE CB, EDELHAUSER HF, HOLLEY GP, GROSSNIKLAUS HE–Madison, Atlanta</td>
</tr>
<tr>
<td>18:36</td>
<td>2427</td>
<td>Consequences of dietary omega-3 polyunsaturated fatty acid deficiency on retinal function and intraocular pressure in the rat</td>
<td>BARDET B, ACAR N, CREUZOT C, BRON AM, BRETIJLON L–Dijon</td>
</tr>
</tbody>
</table>

**Emerald I**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>COS:</td>
<td><strong>Wavefront aberrometry and adaptive optics</strong></td>
<td>17:30 – 19:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jean-Jacques GICQUEL, Pierre Jean PISELLA</td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td>2431</td>
<td>Visual function after cataract surgery in patients with an aspherical lens without spherical aberration</td>
<td>PISELLA PJ–Tours</td>
</tr>
<tr>
<td>17:45</td>
<td>2432</td>
<td>Wavefront aberrometry advances in refractive surgery</td>
<td>COCHENER B–Brest</td>
</tr>
<tr>
<td>18:00</td>
<td>2433</td>
<td>Wavefront aberrations variations with accommodation</td>
<td>GICQUEL JJ–Poitiers</td>
</tr>
<tr>
<td>18:15</td>
<td>2434</td>
<td>Adaptive optics applied to the vision simulator</td>
<td>CHATEAU N–Orsay</td>
</tr>
<tr>
<td>18:30</td>
<td>2435</td>
<td>Custom wavefront contact lenses</td>
<td>LOPEZ-GIL N–Murcia</td>
</tr>
<tr>
<td>18:45</td>
<td>2436</td>
<td>Colorimetric comparison between different filtered IOLs and human crystalline lenses at various ages</td>
<td>MENCUCI R, MENCHINI U, ROMANO G, MONICI M, FUSI F, GUASTI A, MERCATELLI L–Florence</td>
</tr>
</tbody>
</table>
### Emerald II

**FP**

**MBGE: Free Papers 3**
Seang-Mei SAW, Marcela VOTRUBA

<table>
<thead>
<tr>
<th>Time</th>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>2441</td>
<td>The effect of upregulated LOX and LOXL2 on inflammation and fibrosis in a laser induced CNV model</td>
<td>VAN DE VEIRE S, VAN BERGEN T, VANDEWALLE E, MOONS L, SMITH V, OGG S, STALMANS I-Leuven, Palo Alto</td>
</tr>
<tr>
<td>17:42</td>
<td>2442</td>
<td>Is inhibition of VEGF165 sufficient to inhibit scar formation after trabeculectomy?</td>
<td>VAN BERGEN T, VAN DE VEIRE S, VANDEWALLE E, MOONS L, STALMANS I-Leuven</td>
</tr>
<tr>
<td>17:54</td>
<td>2443</td>
<td>Intraocular pressure and associated factors in a Central Indian population. The Central India Eye and Medical Study</td>
<td>JONAS JB, NANGIA V, MATIN A, SINHA A, KULKARNI M, BHOJWANI K-Mannheim, Nagour</td>
</tr>
<tr>
<td>18:06</td>
<td>2444</td>
<td>Screening history in those requiring fast track referral for proliferative diabetic retinopathy (PDR) in the ni diabetic retinopathy screening programme</td>
<td>HART PM, SAXENA R, JOHNSTON SE, FLYNN C, MCCLEDDUP P-Belfast</td>
</tr>
</tbody>
</table>

### Mediterranean I

**FP**

**G: Pressure and blood flow in glaucoma**
Carlos MARQUES-NEVES, Anna-Maria STEVENS

<table>
<thead>
<tr>
<th>Time</th>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>2451</td>
<td>Aging and glaucoma</td>
<td>PILLUNAT L-Dresden</td>
</tr>
<tr>
<td>17:42</td>
<td>2452</td>
<td>Association between optic nerve head blood flow as assessed with Laser Doppler Flowmetry and mean arterial blood pressure in glaucoma, ocular hypertension and healthy control subjects</td>
<td>SCHMIDL D, HOMMER A, RESCH H, FUCHSJAEGER-MAYRL G, GARHOFER G, VAAS C, SCHMETTERER L-Vienna</td>
</tr>
<tr>
<td>17:54</td>
<td>2453</td>
<td>Vascular endothelial dysfunction in primary open angle glaucoma</td>
<td>CELLINI M, GIZZI C, STROBB E, FAVARETTO E, FILIPPINI M, PALARETI G, CAMPOS EC-Bologna</td>
</tr>
<tr>
<td>18:00</td>
<td>2454</td>
<td>Sympathetic influence on intraocular pressure</td>
<td>MARQUES-NEVES C, GONCALVES C, LARANJO S, SANTOS M, ROCHA I-Lisbon</td>
</tr>
<tr>
<td>18:06</td>
<td>2455</td>
<td>Sympathetic variability of intraocular pressure of glaucoma patients evaluated by wavelets</td>
<td>MARQUES-NEVES C, GONCALVES C, LARANJO S, SANTOS M, FIGUEIREDO A, ROCHA I-Lisbon</td>
</tr>
<tr>
<td>18:12</td>
<td>2456</td>
<td>Measurement of IOP with radiowave telemetry</td>
<td>TODANI A, FAVA M, BEHLAU I, MELKI S, DOHLMAN CH-Boston</td>
</tr>
<tr>
<td>18:18</td>
<td>2457</td>
<td>Factors affecting ocular rigidity in normal human eyes</td>
<td>DASTIRIDOU AI, GNIS H, KARYOTAKIS NG, TSLIMBARIS M, PALLIKARIS IG-Heraklion</td>
</tr>
<tr>
<td>18:24</td>
<td>2458</td>
<td>Sensitivity of applanation tonometry readings to the geometrical parameters of the sclera and the shape of the cornea</td>
<td>VORONKOVA E, BAUER S, TIPYASEV A-St-Petersburg</td>
</tr>
</tbody>
</table>

### Adria

**SIS**

**RV: Retinal oxygenation in health and disease**
Einar STEFANSSON, ConstantiN POURNARAS

<table>
<thead>
<tr>
<th>Time</th>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>2461</td>
<td>Retinal oxygenation in diabetic retinopathy</td>
<td>HARDARSON SH, OLAFSDOTTIR OB, KARLSSON RA, BEACH JM, EYSTEINSSON T, BENEDIKTSSON JA, STEFANSSON E-Reykjavik</td>
</tr>
<tr>
<td>17:45</td>
<td>2462</td>
<td>Retinal photocoagulation and oxygenation</td>
<td>POURNARAS CJ-Geneva</td>
</tr>
<tr>
<td>18:00</td>
<td>2463</td>
<td>Retinal and optic nerve oxygenation and carbonic anhydrase inhibition</td>
<td>LA COUR M, STEFANSSON E-Copenhagen, Reykjavik</td>
</tr>
<tr>
<td>18:15</td>
<td>2464</td>
<td>Noninvasive oximetry and glaucoma</td>
<td>OLAFSDOTTIR OB, HARDARSON SH, GOTTFREDSDOTTIR MS, HARRIS A, STEFANSSON E-Reykjavik, Indianapolis</td>
</tr>
<tr>
<td>18:30</td>
<td>2465</td>
<td>Retinal vessel oximetry made simple and reliable - principle, performance and clinical results</td>
<td>HAMMER M, SCHWEITZER D-Jena</td>
</tr>
<tr>
<td>18:45</td>
<td>2466</td>
<td>Retinal vessel oximetry using sequential and 'snapshot' hyperspectral imaging</td>
<td>MCNAUGHT A, HARVEY A, MAYO G, MORDANT D, ALLABOUD I, RITCHIE P-Cheltenham, Edinburgh</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Title</td>
<td>Presenter(s)</td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>17:30</td>
<td>2471</td>
<td>Need for training the trainers programme in harmonisation of education</td>
<td>HAWLINA M–Ljubljana</td>
</tr>
<tr>
<td>17:42</td>
<td>2472</td>
<td>The role of the professor as leader and promotor of science</td>
<td>PRAUSE JU–Copenhagen</td>
</tr>
<tr>
<td>17:54</td>
<td>2473</td>
<td>Needs from residents’ perspective and SOE YO</td>
<td>KHAWAJA A–London</td>
</tr>
<tr>
<td>18:06</td>
<td>2474</td>
<td>EBO curriculum development</td>
<td>CREUZOT C–Dijon</td>
</tr>
<tr>
<td>18:18</td>
<td>2475</td>
<td>How to conduct a good viva voce?</td>
<td>ACLIMANDOS W–London</td>
</tr>
<tr>
<td>18:30</td>
<td>2476</td>
<td>How to teach residents to teach and to select proper residents for this goal</td>
<td>VASSILEVA P–Sofia</td>
</tr>
<tr>
<td>18:42</td>
<td>2477</td>
<td>Professionalism and appraisal</td>
<td>DUA HS–Nottingham</td>
</tr>
</tbody>
</table>
THURSDAY

Anatomy/Cell Biology
Moderators: Saeed AKHTAR, Roberto GALLEGOS-PINAZO, Luc MISSOTINN, Gjis VRESEN

201 Magnetic resonance imaging vs. ultrasound biomicroscopy in the equatorial plane in human eye
KUSNYERIK A, RESCH MD, WILKE R, KLOSE U, BODA K, NEMETH J, SVIGEGER I, PREINER E–Budapest, Tuebingen, Siegen

202 The correlation between central corneal thickness, ocular and general parameters
GALMAUSKA I, GALAITSE I, JOUDITEI K, TUTKIVIENI E, ASOKUS R–Viljus

203 Comparison of the corneal thickness measured by anterior segment optical coherence tomography and specular microscope versus ultrasound pachymetry
KRUKOYSE R, GALMAUSKA I, JOUDITEI K, PAJALULI M, GALAITSE I, ASOKUS R–Viljus

204 Ultrastructural features of free shrew cornea-collagen fibrils and proteoglycans
ALMUBRAD T, AKHTAR S, BRON AJ–Riyadh, Oxford

205 Treatment of ocular surface injuries by the transfer of limbal and mesenchymal stem cells growing on nonaffinitive scaffolds
HOLAN I, ZAUGEOVA A, LENGOVA A, POKORNIA K, SVOBODOVA E, KRULOVA M–Prague

206 Changes in expression of matrix metalloproteinases 1 and 8 in corneal neural epithelium after UV irradiation
ARDAN T, CEKOVA J–Prague

207 The influence of pollen proteases on human conjunctival cells
RABENSTEINER DF, SCHMIT O, SPEHSEYHOFER EM, TRUMMER G, WACHSADNER C, KIRCHENGAST I, WEDRICH A–Graz

208 Trabeocular meshwork contribution to the uveal scleral outflow
KARLOVA E, ZOLOTARYOV A, NIKOLAYEVA G–Samara

209 Cell connections between lens fibres in the posterior pole of human and bovine lenses
VAN MARLE G, VRESEN G, HOEBEN K–Amsterdam, Leiden

210 Human anterior lens capsule epithelial cell contractions and bovine lenses
KARLOVA E, ZOLOTARYOV A, NIKOLAYEVA G–Samara

211 Macroglial changes in ipsilateral and contralateral rat retina in adeno-associated virus

212 The human choroid possesses substance P and calcitonin gene-related peptide intrinsic neurons
TRIVINO A, DE HOZ R, ROJAS B, SALAZAR JJ, RAMIREZ AI, GALLEGO B, RAMIREZ JM–Madrid

213 Pleiotropic effects of statins on the morphology of choroidal endothelial cells and vascular smooth muscle cells in hypercholesterolemic rabbits
RAMIREZ AI, ROJAS B, SALAZAR JJ, RAMIREZ AI, DE HOZ R, GALLEGO B, TRIVINO A–Trivino, Avila

214 Retinal ganglion cells in culture induced to die by insults of hydrogen peroxide (H2O2), rotenone and glutamate/buthionine-sulfloxime (GB) are differently protected by the flavonoids, epicatechin gallate (EG) epigallocatechin gallate (EGCG) and genistein
TRIVINO A, DE HOZ R, ROJAS B, SALAZAR JJ, RAMIREZ AI, GALLEGO B, RAMIREZ JM–Madrid

215 Proteasome inhibitor-induced protein aggregation is regulated via HSP90, HDACs and microtubulus stability in ARPE-19 cells
KAARNSRANTA K, KYRÔHVEN T, VIIRI J, UUSTALO H, TRIVINO A–Kuopio, Tampere

216 HSP70 and p62/SQSTM1 regulate differently autophagy clearance in ARPE-19 cells
VIIRI J, HYYTINEN J, KYRÔHVEN T, SALMINEN A, KAARNSRANTA K–Kuopio

217 Human retinal pigment epithelium expressed light junction markers in spheroid cultures
PINILLA I, WRIGHT LS, GARCIA MARTIN E, GAMM DM, CUENCA NICOLAS–Zaragoza, Madison, Alicante

218 Inhibition of Notch pathway enhances photoreceptor commitment from cultured retinal stem cells
MONTAVON P, ARSENEVJETI Y–Lonsanne

219 A new potential pharmacological target in diabetic retinopathy: the HuR pathway
AMADIO M, BUCCOLI C, DRAGO F, GOVONI S, PASCALE A–Pavia, Catania

Glucoma
Moderator: Gerhard GARHOFER, Gabriele FUCHS-JÄGER–Mayr

220 Rarebit visual field follow-up in pediatric glaucoma
MARTIN L, LUNDVALL NILSSON A–Stockholm

221 The retinal nerve fiber layer and the optic nerve head morphology after glaucoma surgery
GARCÍA MARTIN E, PINILLA I, GIL-ARRIBAS L, MARTIN L–Stockholm

222 Vascular endothelial dysfunction in primary open angle glaucoma
CELLINI M, GIZZI C, STROBBIE E, FAVARETTO E, FILIPPINI M, PALARETI G, CAMPOS EC–Bologna

223 Sympathetic influence on intraocular pressure
MARGARE-NEVES C, GONÇALVES C, LARANJO S, SANTOS M, ROCHA J–Lisbon

224 Sympathetic variability of intraocular pressure of glaucoma patients evaluated by waves
MARGARE-NEVES C, GONÇALVES C, LARANJO S, SANTOS M, FIGUEREDO A, ROCHA J–Lisbon

225 Measurement of IOP with radio wave telemetry
TODANI A, FAVA M, BEHRAUT S, MOLHAN CH–Boston

226 Factors affecting ocular rigidity in normal human eyes
DASTIRDOU AI, GINS H, KARYOTAKIS NG, TSLIMBARIS M, PALLIKARIS IG–Heraklion

227 Correlation between Goldmann application tonometry and rebound tonometry in relation to central corneal thickness

228 On the dependence of outflow facility on intraocular pressure in the living human eye
KARYOTAKIS NG, GINS H, LIMPOPOULOU A, DASTIRDOU AI, TSLIMBARIS M, PALLIKARIS IG–Heraklion

229 IOP evaluation in glaucoma patients after phacoemulsification
STOJANOVICH A, TSLIMBARIS M, PALLIKARIS IG–Heraklion

230 Functional correlation between retinal sensitivity threshold values of standard automated perimetry in glaucoma
GIERRE MONCLES N, PIERO CALVO E, EGEA ESTOFINAN MC, FERRERAS A, PIELLE LE–Zaragoza

231 SITA-SWAP and SITA-SAP in glaucoma suspects
MILANO G, BOSOLESI L, COLOMBO M, BORDIN M, LANTIERI S, RAIMONDI M, ROSSI G–Pavia

232 Relationship between frequency doubling perimetry indices and optic nerve head parameters measured with the Heidelberg retina tomograph 3
FERRERAS A, CALVO PEPE P, PAILAR IN, ABADIA B, FOGAGNOLO P, FIGUS M, PABLLE LE–Zaragoza, Rome, Pisa

233 Relationship between the automated classification of Heidelberg retina tomograph and main indices of short-wavelength automated perimetry
FERRERAS A, PAILLE LE, PAILAR IN, POLO V–Zaragoza

234 Reproducibility of optic disc measurements acquired with spectral-domain optical coherence tomography
FERRERAS A, CALVO PEPE P, PAILAR IN, FIGUS M, PABLLE LE–Zaragoza, Rome, Pisa

235 An analysis of retinal nerve fiber layer with ImageJ program
KIM S, KIM H, SHON Y–Seoul

236 Differences in retinal nerve fiber layer measurements between time domain optical coherence tomography (OCT) and spectral domain OCT in patients with type 1 diabetes without retinopathy
IDOPE M, GARCIA MARTIN E, PINILLA I, GIL-ARRABAS L, FUERTES LAZARO M–Zaragoza

237 Glaucomatous optic neuropathy and oscillatory potentials in the ERG to long-duration stimuli
KAZARYAN AA–Moscow

238 Anterior segment optical coherence tomography imaging of OclerusGenTM implants in trabeculectomy blebs
BOYER PY, NARAYANASWAMY A, ZHEQI CE, TAN TA, HTOOM HM, AUNG T–Singapore

239 Is subconjunctival inflammation associated with failure of filtering surgeries?
VERONESE RODRIGUES M, FERTZU FURTADO JM, GARCIA SOARES E, DEGAIDE NHS, FELIPE CROSTA D, DONADI EA, SILVA DE PAULO J–Ribeirão Preto / São Paulo
Molecular Biology/Genetics/Epidemiology

Moderators: Marcela VOTRUBA, Amanda CHURCHILL

240 Gene therapy mediates cone rescue and rejuvenation in the R91W mutant form of Rpe65 deficiency mice
ARSENJEVIC Y, CRIPPA S, PIGNAT V, SAMARDZJA M, KOŠTIC C–Lauzanne, Zürich

241 Importance of electroretinogram in bull’s eye maculopathy
HALFELD FURTADO DE MENDONÇA R, KOK F, ROSENBERG S, YUKIHKO TAKAHASHI W–São Paulo

242 LOC387715/ARMS2 studies – gene sequencing as a procedure of choice
WYLEGALA E, TEPER S, NOWINSKA A–Katowice

243 Hunter’s syndrome and buphthalmos in a girl: an unusual ophthalmic association
SETHI B, BHARTIYA S, MEHTA M, CHANDRA M, GHOSE S–Delhi

244 Relationship between IOP and age in the Salzburg-Moorfields-Collaborative Glaucoma Study
REITSAMER HA, HITZL W, WINTERSTEINER CH, HORNKYEWYCS K, ABRI S, GRABNER G–Salzburg

245 Major eye diseases and risk factors associated with systemic hypertension in an adult Chinese population: the BEijing eye study
LÜBONTI T, JONAS JB, WANG X, XU L, WONG TY, CUI T, LI Y, CHENG S–Mannheim, Beijing, Melbourne

246 Nitric oxide synthesis is related to astroglial cell cycle in the mouse retina via p53 gene regulation

247 Screening history of those with severe visual impairment due to diabetic retinopathy
HART PM, HART PW, JACKSON AJ–Belfast, Manchester

248 Symmetry of retinopathy in the NI diabetic retinopathy screening programme NIDRSP
HART PM, STEVENSON MR–Belfast

249 Glucose-6-phosphate dehydrogenase (G6PD) deficiency and proliferative diabetic retinopathy in a Sardinian male population, Italy
PINNA A, CONTINI E, GIACOBONI M, CARTA A, SOLINAS G–Sassari, Parma

250 Genetic and phenotypic analyses of retinills pigmentosa in northern Tunisia

251 Phenotype-genotype correlations of TGFβ1 in Asian patients
CHAI SM, VITHANA E, MEHTA J, TAN D, TEN A–Singapore

252 Central corneal thickness and its association with ocular and general parameters in Indians. Central India Eye and Medical Study
JONAS JB, NANGIA V, SINHA A, MATIN A, KULKARNI M–Mannheim, Nagpur

253 Differential association of cataract sub-types with obesity and FTO polymorphisms
LIU L, TAI E, AUNG T, TAY W, SAW SM, SEIELSTAD M, WONG TY–Singapore

254 A novel mitochondrial NDUFS6 gene mutation m.13042G>A in Leber hereditary optic neuropathy
PAJALTIER A, STRIN-KRAHUC B, BRECELIJ I, HAWUNA M–Ljubljana

255 Severe ocular trauma cases: types and incidence
STOJANOVIC N, TSOLAKI F, TACHAOS P–Thessaloniki

256 Ocular features and management in the mucopolysaccharidoses
PINELLO L, DE BELVIS V, MAZZAROLO M, SCARPA M–Padua

Physiology/Biochemistry/Pharmacology

Moderators: Neville OSBORNE, Leopold SCHMETTERER

257 Cytochrome C oxidase expression in retinal rod outer segment disks
BARABINO S, PANFOLI I, CALZIA D, ROLANDO M, MORELLI A–Genoa

258 Vasopressin receptors in ocular tissues and their impact on ocular hydrodynamics

259 In vitro transcorneal and transscleral diffusion of radiolabeled compounds in human and rabbit cornea and in human, monkey, dog, and rabbit sclera
STUBLER CB, EDHELHAUSER HF, HOLLEY GP, GROSSNIKLAUS HE–Madison, Atlanta

260 Consequences of dietary omega-3 polyunsaturated fatty acid deficiency on retinal function and intraocular pressure in the rat
BARDOT B, ACAR N, CREUZET C, BRON AM, BRETELION L–Dijon

261 Butaprost, a prostaglandin EP2 receptor agonist, counteracts the negative effect of serum deprivation to retinal ganglion cells
KANG K, OSBORNE NN–Oxford

262 N-Acetyl cysteine (NAC) attenuates neuronal cell death in culture not solely by up regulating glutathione (GSH)
ABDUL MAJID AS, OSBORNE NN–Oxford

263 Ocular and plasma bioavailability of different memantine formulations after periocular administration
PERIOET ALYOE E, BREGANTE UCEDO MA, PEREZ OLIVAN S, PUENTE BAYO B–Zaragoza

264 Choroidal blood flow regulation during a latanoprost-induced decrease in intraocular pressure

265 Urocinfinol relaxes the iris sphincter muscle
ROCHA DE SOUSA A, TAVARES-SILVA M, FONSECA S, CARDOSO S, LEITE-MOREIRA AF–Porto

266 Choroidal blood flow response to hyperoxia and hypercapnia in patients with obstructive sleep apnoea syndrome

267 Intravitreal L-arginine injection reverses the retinal arteriolar vasoconstriction that occurs after experimental acute branch retinal vein occlusion
MENRINOS E, PETROPOLIOS I, MANGIORIS G, PAPADOPOULOU DN, PORTARAZO C–Geneva

268 The effect of betablockers on ocular hemodynamics in anesthetized rabbits
RUNG EW, BOGNER B, STROHMAIER C, GRABNER G, REITSAMER HA–Salzburg

269 A rat model to study choroidal blood flow
STROHMAIER C, RUNG EW, BOGNER B, GRABNER G, REITSAMER HA–Salzburg

270 Retrobarbar flow velocities in open angle glaucoma and their association with mean arterial blood pressure

271 Citric acid suppresses UV-8-induced interleukin-6 secretion and cytotoxicity in human corneal and conjunctival epithelial cells in vitro

272 Combined effects of aging and a pro-diabetic diet on retinal function in a murine model of aging of the human eye
SIMON E, ACAR N, BRON AM, CREUZET C, BRETELION L–Dijon

273 Efficacy and safety of topical cyclopentolate versus vehicle in venous keratoconjunctivitis in children

EVER 2009 programme
<table>
<thead>
<tr>
<th>Europa A</th>
<th>RV: Vitreoretinal surgery: from past to future</th>
<th>08:15 – 09:45</th>
</tr>
</thead>
<tbody>
<tr>
<td>FP</td>
<td>Philippe KOCH, Elisabeth VAN AKEN</td>
<td></td>
</tr>
<tr>
<td>08:15</td>
<td>3111</td>
<td>Surgical experience and outcome of scleral buckling procedures in retinal detachment&lt;br&gt;<strong>ARNDT C, FRANCERIE-SADDIKI V, BRUGNIART C, SEGAL A, DUCASSE A–Reims</strong></td>
</tr>
<tr>
<td>08:27</td>
<td>3112</td>
<td>Investigation of particular surgical steps in epiretinal prostheses implantation procedure in pigs&lt;br&gt;<strong>IVASTINOVIC D, GEORGI T, HORNIG R, WEDRICH A, VELIKAY-PAREL M–Graz, Bonn</strong></td>
</tr>
<tr>
<td>08:39</td>
<td>3113</td>
<td>Sutureless encircling band – biomechanical calculations and clinical experience&lt;br&gt;<strong>MAIER M, FEUCHT N, WINKLER VON MOHRENFEELS C, KOTLIAR KE, LOHMANN CP–Munich</strong></td>
</tr>
<tr>
<td>08:51</td>
<td>3114</td>
<td>Electronic subretinal implants allow blind retinitis pigmentosa patients to read letters and recognize the direction of fine stripe patterns&lt;br&gt;<strong>ZRENNER E, WILKE R, BARTZ-SCHMIDT K, BENAÎV H, BESCH D, GEKLER F, KOCH J, PORUBSKÁ K, SACHS H, GREPPMAIER U, HARSCHER A, WILHELM B–Tübingen, Dresden, Reutlingen</strong></td>
</tr>
<tr>
<td>09:03</td>
<td>3115</td>
<td>First experience with The IRIS retinal implant system&lt;br&gt;<strong>VELIKAY-PAREL M, IVASTINOVIC D, LANGMANN G, HORNIG R, GEORGI T, WEDRICH A–Graz, Bonn</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Europa B</th>
<th>VEP: Colour vision</th>
<th>08:15 – 09:45</th>
</tr>
</thead>
<tbody>
<tr>
<td>FP</td>
<td>Bart LEROY, Werner SPILEERS</td>
<td></td>
</tr>
<tr>
<td>08:15</td>
<td>3121</td>
<td>The study of chromatic and achromatic VEP in the first year of life&lt;br&gt;<strong>TEKAVCIC POMPE M, STRIN KRAJNC B, BRECELJ J–Ljubljana</strong></td>
</tr>
<tr>
<td>08:27</td>
<td>3122</td>
<td>Acquired loss of chromatic sensitivity&lt;br&gt;<strong>BARBUR J–London</strong></td>
</tr>
<tr>
<td>08:39</td>
<td>3123</td>
<td>Differential effects of ageing on foveal and peripheral colour vision&lt;br&gt;<strong>RAUSCHER F, EDGAR D, BARBUR J–London</strong></td>
</tr>
<tr>
<td>08:51</td>
<td>3124</td>
<td>Chromatic sensitivity in subjects with diabetes&lt;br&gt;<strong>O’NEILL-BIBA M, RODRIGUEZ-CARMONA M, RAUSCHER F, BARBUR J, SIVAPRASAD S–London</strong></td>
</tr>
<tr>
<td>09:03</td>
<td>3125</td>
<td>Pre-receptoral spectral absorption, healthy ageing and pre-clinical indications of retinal disease&lt;br&gt;<strong>KONSTANTAKOPOULOU E, BARBUR J–London</strong></td>
</tr>
<tr>
<td>09:15</td>
<td>3126</td>
<td>On the effectiveness of cone mosaic geometry in sampling patterns near the Nyquist frequency&lt;br&gt;<strong>GINIS H, PERDIKARI K, PALLIKARI A–Heraklion</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Emerald I</th>
<th>COS: Ocular surface and dry eye</th>
<th>08:15 – 09:45</th>
</tr>
</thead>
<tbody>
<tr>
<td>FP</td>
<td>Pierre Jean PISELLA, Philippe KESTEYLN</td>
<td></td>
</tr>
<tr>
<td>08:15</td>
<td>3131</td>
<td>Pterygium surgery long term follow-up&lt;br&gt;<strong>WOOD T, WILLIAMS E, WILLIAMS B–Memphis, Atlanta</strong></td>
</tr>
<tr>
<td>08:39</td>
<td>3133</td>
<td>Detection of osmoprotective effect of topical compatible solutes on ocular surface epithelia&lt;br&gt;<strong>CALIENNO R, NUBILE M, LANZINI M, CURCIO C, COLESANTE M, CIAFRE M, MASTROPASQUA A–Chieti, Pescara</strong></td>
</tr>
<tr>
<td>08:51</td>
<td>3134</td>
<td>Alcohol vs. mechanical debridement in the treatment of corneal erosion: an electron microscopic study&lt;br&gt;<strong>PALADINI I, BRAHIMI B, MENCHINI U, DUA HS, ROMAGNOLO P, MENCUCCI R–Florence, Nottingham</strong></td>
</tr>
<tr>
<td>09:03</td>
<td>3135</td>
<td>Lymphocyte and markers of inflammation detection in the conjunctival epithelium of patients with dry eye by enhanced flow cytometry&lt;br&gt;<strong>BARABINO S, MONTALDO E, SOULIGNANI F, MINGARI C, ROLANDO M–Genoa</strong></td>
</tr>
<tr>
<td>09:09</td>
<td>3136</td>
<td>Sutureless and glue free conjunctival autograft in pterygium surgery&lt;br&gt;<strong>DE WIT DW, MOORE J–Cambridge, Belfast</strong></td>
</tr>
<tr>
<td>09:15</td>
<td>3137</td>
<td>Ocular surface findings in patients with congenital aniridia&lt;br&gt;<strong>DE LA PAZ MF, BLANCO Z, ALVAREZ J–Barcelona</strong></td>
</tr>
<tr>
<td>09:21</td>
<td>3138</td>
<td>Compare optical with photometry measures of tear film lipid layer&lt;br&gt;<strong>NEPP J, BENZ P, NEILL B, SCHAUERSBERGER J–Vienna</strong></td>
</tr>
<tr>
<td>09:27</td>
<td>3139</td>
<td>Evaluation of spatial contrast sensitivity after the instillation of dicyclofenac eye drops&lt;br&gt;<strong>KARAMPATAKIS V, CHATZIMPALIS T, KORDALI P, KALPATSANIDIS A, STAMOULAS K–Thessaloniki</strong></td>
</tr>
</tbody>
</table>
### Emerald II

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIS</td>
<td><strong>LC: Diabetic cataract: mechanisms and management</strong></td>
<td>Irina OIROSOVA, Peter KADOR</td>
</tr>
<tr>
<td>08:15</td>
<td>3141</td>
<td>Loss of thioredoxin activity as an important contributor to oxidative stress in lens of diabetic rats LOU M, LECHNER J, XING K, KADOR PF—Lincoln, Omaha</td>
</tr>
<tr>
<td>08:37</td>
<td>3142</td>
<td>Treating diabetic dogs with topical Kinostat™ for cataracts: proof of concept clinical trial KADOR PF, ROBIN-WEBB T, BRAS D, KETERING KL, WYMAN M—Omaha, Worthington, Columbus</td>
</tr>
<tr>
<td>08:59</td>
<td>3143</td>
<td>Anticataract effect as a predictor of drug efficacy against early diabetes-induced retinal changes OIROSOVA IG—Baton Rouge</td>
</tr>
<tr>
<td>09:21</td>
<td>3144</td>
<td>Differences in lens opacification in type 2 diabetic patients on oral anti-diabetic medication or insulin therapy WEGENER A, KREMER J, MÜLLER-BREITENKAMP R, LASER H—Bonn</td>
</tr>
</tbody>
</table>

### Mediteranea I

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>FP</td>
<td><strong>G: Glaucoma surgery</strong></td>
<td>Ingeborg STALMANS, Alain BRON</td>
</tr>
<tr>
<td>08:15</td>
<td>3151</td>
<td>Preoperative topical non-steroidal anti-inflammatory drug or steroid and clinical outcomes after trabeculectomy STALMANS I, SPIELBERG L, VANGINDERDEUREN R, ZEYEN T, BREUSEGEM C—Leuven</td>
</tr>
<tr>
<td>08:27</td>
<td>3152</td>
<td>Microplasmin improves surgical outcome in a rabbit model for trabeculectomy VANDEWALLE E, VAN BERGEN T, YOU Y, VAN DE VEIRE S, MOONS L, STALMANS I—Leuven</td>
</tr>
<tr>
<td>08:39</td>
<td>3153</td>
<td>Do patients with normal tension glaucoma have a thinner conjunctiva? VAN GINDERDEUREN R, STALMANS I, SPIELBERG L, ZEYEN T—Leuven</td>
</tr>
<tr>
<td>08:51</td>
<td>3154</td>
<td>Effect of phacoemulsification on the primary open angle glaucoma control after trabeculectomy: a case-control study AZIZ S, SPIRES N, JAY J—Leicester, Glasgow</td>
</tr>
<tr>
<td>09:03</td>
<td>3155</td>
<td>A new technique for diode laser cyclophotocoagulation: short term results SURIANO M, STIRBU O, VILA ARTEAGA J—Valencia</td>
</tr>
<tr>
<td>09:15</td>
<td>3156</td>
<td>Inflammation assessment after selective laser trabeculoplasty (SLT) treatment AYALA M, LANDAU HÖGBECK I, CHEN E—Stockholm</td>
</tr>
</tbody>
</table>

### Adria

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIS</td>
<td><strong>NSPH: Jumping, jiggling and jerking eyes: recognition and management of unusual eye movement disorders</strong></td>
<td>Aki KAWASAKI, François-Xavier BORRUAT</td>
</tr>
<tr>
<td>08:15</td>
<td>3161</td>
<td>Oculopalatal tremor BORRUAT FX—Lausanne</td>
</tr>
<tr>
<td>08:33</td>
<td>3162</td>
<td>Opsoclonus EGGENBERGER E—East Lansing</td>
</tr>
<tr>
<td>08:51</td>
<td>3163</td>
<td>Superior oblique myokymia KAWASAKI A—Lausanne</td>
</tr>
<tr>
<td>09:09</td>
<td>3164</td>
<td>Macrosquare wave jerks EGGENBERGER E—East Lansing</td>
</tr>
<tr>
<td>09:27</td>
<td>3165</td>
<td>Ocular neuromyotonia BOSCHI A—Bruxelles</td>
</tr>
</tbody>
</table>

### Keynote Lecture 2

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Europa A</td>
<td><strong>Age-related macular degeneration: an Alzheimer's disease in the eye?</strong></td>
<td>Kyoko OHNO-MATSUI - Tokyo, Japan</td>
</tr>
<tr>
<td>10:00</td>
<td>3174</td>
<td>Introduction by Carl HERBORT</td>
</tr>
</tbody>
</table>
European Professors of Ophthalmology

EUPO COURSE 2010 • RETINA
October 1-3, 2010 • Athens, Greece
www.eupo.eu

European Association for Vision and Eye Research

EVER 2010
October 6-9, 2010
Crete www.ever.be

2011 > October 5-8, Crete
2012 > October 3-6, Crete
EBOD 2010 Examination

The European Board of Ophthalmology (EBO) Examination 2010 will take place on May 7-8th, 2010 at the: Palais des Congrès de Paris, 2, Place Porte Maillot F-75017 PARIS FRANCE

When?
May 7-8, 2010

Where?
Paris, Palais des Congrès (Porte Maillot)

Application period
From October 1, 2009 till January 31st 2010
Electronic application form (website)

More information...
http://www.ebo-online.org

Joint Congress of

SOE
AAO
4–7 June 2011
Geneva
Switzerland

For further information:
www.soe2011.org
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>RV</td>
<td>Novelties in basic research in the vitreous</td>
<td>SIS Elisabeth VAN AKEN, Marc D DE SMET</td>
</tr>
<tr>
<td>11:00</td>
<td>RV</td>
<td>Hereditary vitreoretinopathies</td>
<td>SNEAD M–Cambridge</td>
</tr>
<tr>
<td>11:18</td>
<td>RV</td>
<td>Protein screening in vitreous samples of patients with retinal vein</td>
<td>AGOSTINI HT, MARTIN G, HANSEN LL–Freiburg</td>
</tr>
<tr>
<td>11:36</td>
<td>RV</td>
<td>Pharmacokinetics of intraocular microplasmin. Revelance to the</td>
<td>DE SMET M–Lausanne</td>
</tr>
<tr>
<td>11:54</td>
<td>RV</td>
<td>Insights into the molecular basis of rhegmatogenous retinal</td>
<td>BISHOP PN–Manchester</td>
</tr>
<tr>
<td>12:12</td>
<td>RV</td>
<td>Transthyretin levels in the vitreous correlate with change in visual</td>
<td>VAN AKEN E, VECKENEER M, DERYCZE L, DELANGHE J–Ghent, Rotterdam</td>
</tr>
<tr>
<td>11:00</td>
<td>VEP</td>
<td>ISCEV Session</td>
<td>Joint M. Colin BARBER, Pierre LACHAPELLE</td>
</tr>
<tr>
<td>11:00</td>
<td>VEP</td>
<td>Target oriented selection of electrophysiological endpoints in</td>
<td>ZRENNER E, WILHELM B, PETERS T, KURTENBACH A–Tübingen</td>
</tr>
<tr>
<td>11:18</td>
<td>VEP</td>
<td>Separating physiological from pathological effects of drugs tested</td>
<td>PERLMAN I–Haifa</td>
</tr>
<tr>
<td>11:36</td>
<td>VEP</td>
<td>The mysterious a-wave</td>
<td>LACHAPELLE P, GARON ML, POLOSA A, ZIMAK E–Montréal, Québec</td>
</tr>
<tr>
<td>11:54</td>
<td>VEP</td>
<td>Electrophysiological assessment of optic neuropathies in</td>
<td>HAWLINA M, BRECELJ J–Ljubljana</td>
</tr>
<tr>
<td>12:12</td>
<td>VEP</td>
<td>Novel mutations and electrophysiological findings in RGS9 and R9AP</td>
<td>HOLDER GE, MICHAELIDES M, LI Z, RANA NA, RICHARDSON EC, HYKIN PG, MOORE AT,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>associated retinal dysfunction [Bradyopsia].</td>
<td>WEBSTER AR–London</td>
</tr>
<tr>
<td>11:00</td>
<td>COS</td>
<td>Anterior Segment Imaging</td>
<td>SIS Jean-Jacques GICQUEL, Mario NUBILE</td>
</tr>
<tr>
<td>11:00</td>
<td>COS</td>
<td>Ultrasound biomicroscopy for the analysis of the anterior segment</td>
<td>PEDROTTI E–Verona</td>
</tr>
<tr>
<td>11:15</td>
<td>COS</td>
<td>Anterior segment OCT in corneal diseases and surgery</td>
<td>NUBILE M–Chieti</td>
</tr>
<tr>
<td>11:30</td>
<td>COS</td>
<td>In vivo confocal microscopy of the cornea and conjunctiva</td>
<td>BAUDOUIN C–Boulogne Billancourt</td>
</tr>
<tr>
<td>11:45</td>
<td>COS</td>
<td>Diffuse keratoconjunctival diseases: an in vivo confocal microscopic</td>
<td>DUA HS–Nottingham</td>
</tr>
<tr>
<td>12:00</td>
<td>COS</td>
<td>Anterior segment OCT versus UBM in the surgical management of</td>
<td>GICQUEL JJ–Poitiers</td>
</tr>
<tr>
<td>12:15</td>
<td>COS</td>
<td>Anterior segment OCT in glaucoma</td>
<td>CIANCAGLINI M</td>
</tr>
</tbody>
</table>
**FRIDAY**

**Emerald II**

**LC: Straylight in the human eye - Small versus large angle domain**

11:00 – 12:30

**SIS**

Ralph MICHAEL, Harilaos GINIS

11:00 3241 The different domains of the point spread function - Small angle vs large angle

VAN DEN BERG TJTP, COPPENS JE, FRANSEN L–Amsterdam

11:15 3242 Challenges in optical measurement of scatter

GINIS H–Heraklion

11:30 3243 Optical simulation of large and small angle scatterers

DE BROUWERE D, GINIS H, PALLIKARIS IG–Galway, Heraklion

11:45 3244 Straylight in function of wavelength and refraction

ROZEMA J, TASSIGNON MJ–Edegem

12:00 3245 Intraocular straylight screening in medical testing centres for driver licence holders in Spain

MICHAEL R, VAN DEN BERG TJTP, BARRAQUER RI–Barcelona, Amsterdam

12:15 3246 Quality of life in cataract patients and the role of stray light

ASPINALL P–Edinburgh

**Workshop**

11:00 – 12:30

**Women in ophthalmology: From bench to boardroom**

Adrienne Graves

Introduction by Bahram BODAGHI

Dr. Adrienne Graves began her career as a visual scientist, with stops at Brown University, Harvard Medical School, University of Michigan, and University of Paris. Her passion for studying the visual system and the pathophysiology of disease processes led her to the pharmaceutical industry. After positions in R&D at Alcon, she is now President/CEO of Santen’s US operations. Dr. Graves credits her time in Paris for expanding her horizons in many ways, including an appreciation for cultural diversity. This is especially important in her role as a corporate officer of a global enterprise based in Japan.

**Adria**

**PO: Pathology-Oncology**

Steffen HEEGAARD, Tero KIVELÄ

11:00 3261 Oncocytic lesions of the ophthalmic region

HEEGAARD S, ØSTERGAARD J, PRAUSE JU–Copenhagen, Roskilde

11:12 3262 A Western blot analysis of P-glycoprotein in retinoblastoma

SETHI S, GHOSE S, PUSHERER N, BAJAJ MS, KAUR J, KASHYAP S, MEHTA M, SAXENA P, CHAWLA B, CHANDRA M–Delhi

11:24 3263 Heterogeneity in uveal melanoma assessed by multiplex ligation-dependent probe amplification (MLPA)

DOPERALA J, COUPLAND SE, DAMATO B–Liverpool

11:36 3264 Revisiting the value of assessing the mitotic rate of choroidal melanoma

COUPLAND SE, DAMATO B–Liverpool

11:48 3265 Granular cell tumour of the lacrimal gland

VON HOLSTEIN SL, ØSTERGAARD J, DAUGAARD S, TOFT PB, HEEGAARD S–Copenhagen, Roskilde

12:00 3266 Immunohistochemical findings and proliferation markers in uveal melanomas after gamma knife radiosurgery

WACKERNAGEL W, MAYER CF, LACKNER EM, SCHNEIDER MR, LANGMANN G, UNGER F, KLEINERT R–Graz

12:06 3267 Ophthalmologic outcome of 40 spheno-orbital meningioma resections: 15 years long-term results

NOCHEZ Y, FRANCOIS P, VELUT S, CARDON A, MAJZOBJ S, JAN M, PISELLA PJ–Tours

**Business meetings of the scientific sections:**

**AGENDA**

1. Report of the chair of section
2. Report of the programme secretary
3. Next year’s meeting:
   - nomination of a section programme secretary
   - proposals of Special Interest Symposia (SIS)
   - proposals for Keynote speakers
4. Comment on the EVER activities
5. Other business

Sandwiches and refreshments

- Anatomy / Cell Biology
- Cornea / Ocular Surface
- Glaucoma
- Immunology / Microbiology
- Lens and Cataract
- Molecular Biology / Genetics / Epidemiology
- Neuro-ophthalmology / Strabismology / Paediatric ophthalmology / History
- Pathology / Oncology
- Physiology / Biochemistry / Pharmacology
- Retina / Vitreous
- Vision Sciences/Electrophysiol./Physiological Optics

In addition to the agenda, the sections NSPH and PO will nominate at least 2 candidates for section chair.
**Europa A**  
**RV: Treatment of age-related macular degeneration**  
13:45 – 15:15

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45</td>
<td>3311</td>
<td>3 intravitreal ranibizumab injections series for the treatment of neovascular age-related macular degeneration (AMD), 18 months follow-up</td>
<td>Gonzalez C, Toulouse</td>
</tr>
<tr>
<td>13:57</td>
<td>3312</td>
<td>Outcome of exudative age-related macular degeneration (ARMD) after 3 intravitreal injections of bevacizumab</td>
<td>Creuzot C, Birot ML, Souchier M, Malvite L, Bron AM, Dijon</td>
</tr>
<tr>
<td>14:09</td>
<td>3313</td>
<td>Combined intravitreal bevacizumab and triamcinolone for exudative age-related macular degeneration</td>
<td>Libondi T, Jonas JB, Golupkina L, SpandaUJ, Schlichtenbrede F, Rensch F, Mannheim</td>
</tr>
<tr>
<td>14:45</td>
<td>3316</td>
<td>Retinal angiomatous proliferation: is intravitreal ranibizumab therapy enough?</td>
<td>Marianov Ic B, Georgoudis P, Mandal K, Patra S, Bristol</td>
</tr>
<tr>
<td>14:51</td>
<td>3317</td>
<td>Combined 23-gauge sutureless pars plana vitrectomy (PPV), injection of recombinant tissue plasminogen activator (rTPA), expansile gas and bevacizumab treating acute subretinal haemorrhage (SRH) in exudative AMD</td>
<td>Maier M, Perz C, Feucht N, Konrad J, Winkler von Mohrenfels C, Lohmann CP, Munich</td>
</tr>
</tbody>
</table>

**Europa B**  
**VEP: Electrophysiology**  
13:45 – 15:15

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45</td>
<td>3321</td>
<td>Findings in electrooculography and multifocal electroretinography in patients after bevacizumab treatment for age-related macular degeneration</td>
<td>Mankowski W, Katowice</td>
</tr>
<tr>
<td>13:57</td>
<td>3322</td>
<td>Importance of electron microscopy in neuronal ceroid lipofuscinosis</td>
<td>Halfeito Furtado de Mendonca R, Kok F, Rosenberg S, Yukihiko Takahashi W, São Paulo</td>
</tr>
<tr>
<td>14:21</td>
<td>3324</td>
<td>Accommodation and pupillary response in the reading of texts with varying cognitive demand</td>
<td>Mihelicic M, Aalen</td>
</tr>
<tr>
<td>14:45</td>
<td>3326</td>
<td>Comparison of refractive cylinder and corneal cylinder in aphakic eyes</td>
<td>Padrick T, Packer, MD, FACS M, Aliso Viejo, Eugene</td>
</tr>
</tbody>
</table>

**Emerald I**  
**COS: Refractive surgery and anterior segment imaging**  
13:45 – 15:15

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45</td>
<td>3331</td>
<td>Central corneal thickness (CCT) and intraocular pressure (IOP) in myopic adult Chinese</td>
<td>Kachanov A, Balashhevich L, Bauer S, Zimin B, Golovatenko S, Teiui Z, Wang X, St.-Petersburg, Daqing, Harbin</td>
</tr>
<tr>
<td>13:57</td>
<td>3332</td>
<td>Validation and use of simulated corneal endothelium specular microscopy images</td>
<td>Bucht C, Söderberg PG, Manneberg G, Stockholm, Upsala</td>
</tr>
<tr>
<td>14:09</td>
<td>3333</td>
<td>Intraocular pressure measurements values in patients who have had uneventful deep anterior lamellar keratoplasty</td>
<td>Dominkja J, Wylegala E, Katowice</td>
</tr>
<tr>
<td>14:21</td>
<td>3334</td>
<td>Technical standardisation to measure the ocular surface lipid layer with Meibometer 550</td>
<td>Nepp J, Benz P, Schauersberger J, Nell B, Vienna</td>
</tr>
<tr>
<td>14:33</td>
<td>3335</td>
<td>A pocket slitlamp</td>
<td>ARMOUR R, Stevenage</td>
</tr>
<tr>
<td>14:45</td>
<td>3337</td>
<td>Simultaneous topo-guided photorefractive keratectomy (PRK) followed by collagen cross-linking (CXL) for the treatment of keratoconus</td>
<td>Kontadakis QA, Kymionis G, Portaiou D, Kounis G, Karavitaki A, Pallikaris I, Heraklion</td>
</tr>
<tr>
<td>14:51</td>
<td>3338</td>
<td>Comparison of morphometric and morphological OCT Visante and UBM potential in anterior segment imaging</td>
<td>Milka M, Wylegala E, Katowice</td>
</tr>
</tbody>
</table>
## Emerald II

**LC: Lens**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45</td>
<td>FP</td>
<td>3341</td>
<td>Antioxidants reduce diabetic damage in bovine lenses in culture</td>
<td>DOVRAT A, BORMUSOV E, DOVRAT Y, CHEVION M-Halfa, Jerusalem</td>
</tr>
<tr>
<td>13:57</td>
<td>FP</td>
<td>3342</td>
<td>Cell death in lens epithelial cells after stimulation of the sigma-2 receptor</td>
<td>KARLSSON JO, JONHEDE S, PETERSEN A, ZETTERBERG M-Gothenburg</td>
</tr>
<tr>
<td>14:09</td>
<td>FP</td>
<td>3343</td>
<td>Nanostructural properties of intraocular lenses (IOLs) – atomic force microscopy (AFM) and Fourier transform infrared spectroscopy (FTIR) investigations</td>
<td>WYLEGALA E, MROZ I, JASTRZEBSKA M, WRZALIK R, MILKA M-Katowice, Wroclaw, Soanowiec</td>
</tr>
<tr>
<td>14:33</td>
<td>FP</td>
<td>3345</td>
<td>The crystalline lens higher fatty acids influence on the lens physical characteristics</td>
<td>KUDRYAVTSEVA Y, CHUPROV A-Kirov</td>
</tr>
<tr>
<td>14:45</td>
<td>FP</td>
<td>3346</td>
<td>Hardness of a crystalline lens and accommodation</td>
<td>CHUPROV A, KUDRYAVTSEVA Y, KUDRYAVTSEV V-Kirov</td>
</tr>
</tbody>
</table>

## Mediterranea I

**G: Glaucoma and disability**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45</td>
<td>SIS</td>
<td>3351</td>
<td>Evaluation of quality of life, and priorities in people with glaucoma</td>
<td>ASPINALL P-Edinburgh</td>
</tr>
<tr>
<td>14:05</td>
<td>SIS</td>
<td>3352</td>
<td>Measuring visual disability in glaucoma</td>
<td>KOTECHA A-London</td>
</tr>
<tr>
<td>14:45</td>
<td>SIS</td>
<td>3354</td>
<td>Fitness to drive in glaucoma patients- Preliminary study results</td>
<td>STEVENS AM, LELOUP E, ZEYEN T-Gent, Leuven</td>
</tr>
<tr>
<td>15:05</td>
<td>SIS</td>
<td></td>
<td>Panel discussion</td>
<td></td>
</tr>
</tbody>
</table>

## Adria

**PO: The IC3D classification of corneal dystrophies and beyond**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45</td>
<td>SIS</td>
<td>3361</td>
<td>IC3D classification of corneal dystrophies</td>
<td>MÖLLER HU-Viborg</td>
</tr>
<tr>
<td>14:00</td>
<td>SIS</td>
<td>3362</td>
<td>How to tell dystrophies of Bowman’s layer (Reis-Bücklers and Thiel-Behnke) from one another</td>
<td>KIVELÄ T-Helsinki</td>
</tr>
<tr>
<td>14:15</td>
<td>SIS</td>
<td>3363</td>
<td>Overview of the TGFBI corneal dystrophies</td>
<td>KLINTWORTH GK-Durham</td>
</tr>
<tr>
<td>14:30</td>
<td>SIS</td>
<td>3364</td>
<td>A variant TGFBI corneal dystrophy from G623D mutation with an unusual amyloidogenic phenotype</td>
<td>AGOSTINI HT, AUW-HÖDRICH C-Freiburg</td>
</tr>
<tr>
<td>14:45</td>
<td>SIS</td>
<td>3365</td>
<td>TGFBI gene mutations in Hungary – polymorphic corneal amyloidosis caused by the novel FS47S mutation</td>
<td>BERTA A, LOSONCZY G, TAKACS L-Debrecen</td>
</tr>
</tbody>
</table>

## Ophthalmic Research Lecture

**Role of the vascular endothelial cell in uveitis**

Justine SMITH - Portland, USA

Introduction by Uwe PLEYER

**Poster session 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
</table>
### Europa A

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>SIS</td>
<td>Tina XIROU &lt;br&gt; <strong>RV: Progress in vitreo-retinal surgery: controversies in macular hole surgery</strong></td>
<td>17:30 – 19:00</td>
</tr>
<tr>
<td>17:30</td>
<td>3411</td>
<td>New perspectives of optical coherence tomography in diagnosis and follow-up of macular holes &lt;br&gt; <strong>KABANAROU SA, XIROU T, KOURENTIS C, KIDESS A, FERETIS E–Athens</strong></td>
<td></td>
</tr>
<tr>
<td>17:45</td>
<td>3412</td>
<td>Macular hole surgery with and without internal limiting membrane peeling &lt;br&gt; <strong>KOURENTIS C, XIROU T, KABANAROU SA, KIDESS A, FERETIS E–Athens</strong></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>3413</td>
<td>Internal limiting membrane staining &lt;br&gt; <strong>KATSIMPRIS J–Patras</strong></td>
<td></td>
</tr>
<tr>
<td>18:15</td>
<td>3414</td>
<td>23G versus 20G for macular hole surgery. Efficacy, safety and patient satisfaction &lt;br&gt; <strong>PAPPAS G–Heraklion</strong></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td>3415</td>
<td>Face down posturing for macular hole surgery. Is it really required? &lt;br&gt; <strong>TRANOS P–Thessaloniki</strong></td>
<td></td>
</tr>
<tr>
<td>18:45</td>
<td>3416</td>
<td>Sulfur hexafluoride (SF₆) versus perfluoropropane (C₃F₈) gas tamponade for macular hole surgery &lt;br&gt; <strong>STEFANIOTOU M–Ioannina</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Europa B

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>Workshop</td>
<td>Graham HOLDER &lt;br&gt; <strong>VEP: Doctor, I see things that aren’t there</strong></td>
<td>17:30 – 19:00</td>
</tr>
<tr>
<td>17:30</td>
<td>3421</td>
<td>The initial consultation &lt;br&gt; <strong>SPILEERS W–Leuven</strong></td>
<td></td>
</tr>
<tr>
<td>17:52</td>
<td>3422</td>
<td>Retinal causes &lt;br&gt; <strong>LEROY BP–Ghent</strong></td>
<td></td>
</tr>
<tr>
<td>18:14</td>
<td>3423</td>
<td>Visual hallucinations and illusions: neurological considerations &lt;br&gt; <strong>BORRUAT FX–Lausanne</strong></td>
<td></td>
</tr>
<tr>
<td>18:36</td>
<td>3424</td>
<td>Electrophysiology &lt;br&gt; <strong>HOLDER GE–London</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Emerald I

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>SIS</td>
<td>Gilles THURET &lt;br&gt; <strong>COS: Corneal endothelium: from biology to graft</strong></td>
<td>17:30 – 19:00</td>
</tr>
<tr>
<td>17:30</td>
<td>3431</td>
<td>Predicted long-term outcome of corneal transplantation &lt;br&gt; <strong>BORDERIE VM–Paris</strong></td>
<td></td>
</tr>
<tr>
<td>17:45</td>
<td>3432</td>
<td>Beyond penetrating keratoplasty: the challenge of endothelial transplantation &lt;br&gt; <strong>BUSIN M–Forlì</strong></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>3433</td>
<td>Experimental assessment of endothelial viability of grafts &lt;br&gt; <strong>THURET G, PIPPARELLI A–Saint-Etienne</strong></td>
<td></td>
</tr>
<tr>
<td>18:15</td>
<td>3434</td>
<td>Endothelial grafts with manually dissected endothelio-Descemet. Eye bank and surgical point of view &lt;br&gt; <strong>MURAINE M–Rouen</strong></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td>3435</td>
<td>Insights into regulation of the human corneal endothelial cell cycle &lt;br&gt; <strong>JOYCE N–Boston</strong></td>
<td></td>
</tr>
<tr>
<td>18:45</td>
<td>3436</td>
<td>Developing gene therapies for corneal endothelial disorders &lt;br&gt; <strong>LARKIN F–London</strong></td>
<td></td>
</tr>
</tbody>
</table>
**Emerald II**

**LC: Oxidation and cataract**

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>Introduction by Marjorie Lou</td>
</tr>
<tr>
<td>17:36</td>
<td>3441 Oxidative stress from in vivo dual waveband exposure to ultraviolet radiation</td>
</tr>
<tr>
<td></td>
<td>SÖDERBERG PG, LI Y, GALICHANIN K, KRONSCHLAGER M–Uppsala</td>
</tr>
<tr>
<td>17:50</td>
<td>3442 Oxidative effects on the glutathione enzyme systems</td>
</tr>
<tr>
<td></td>
<td>LÖFGREN S–Stockholm</td>
</tr>
<tr>
<td>18:04</td>
<td>3443 The role of mitochondrial glutaredoxin-2 in protecting cells against oxidative stress</td>
</tr>
<tr>
<td></td>
<td>LOU M, WU HL–Lincoln</td>
</tr>
<tr>
<td>18:18</td>
<td>3444 Enhanced age-related and diabetes-induced cataract in mice lacking CuZn-superoxide dismutase</td>
</tr>
<tr>
<td></td>
<td>OLOFSSON EM, MARKLUND SL, BÊHNDIG A–Umeå</td>
</tr>
<tr>
<td>18:32</td>
<td>3445 Orally active multi-functional antioxidants for the treatment of cataracts and AMD</td>
</tr>
<tr>
<td></td>
<td>KADOR PF, RANDAZZO J, ZHANG P, BLESSING K–Omaha</td>
</tr>
<tr>
<td>18:46</td>
<td>3446 The ubiquitin proteasome pathway - Repair or degradation of damaged proteins</td>
</tr>
<tr>
<td></td>
<td>FERNANDES R, BENTO C, SEIÇA R, PEREIRA P–Coimbra</td>
</tr>
</tbody>
</table>

**Mediterranea I**

**G: Trabeculectomy, the end of the surgery, but the beginning of the intervention**

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>We’re still under pressure: postoperative hypertony</td>
</tr>
<tr>
<td></td>
<td>STALMANS I–Leuven</td>
</tr>
<tr>
<td>18:00</td>
<td>Help, I’ve been too successful: postoperative hypotony</td>
</tr>
<tr>
<td></td>
<td>ZEYEN T–Leuven</td>
</tr>
<tr>
<td>18:30</td>
<td>Cataract, loss of visual acuity, infection after trabeculectomy</td>
</tr>
<tr>
<td></td>
<td>BRON AM–Dijon</td>
</tr>
</tbody>
</table>

**Adria**

**IM: Gene therapy in ocular inflammation**

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>Non-viral strategies of intra-ocular gene delivery</td>
</tr>
<tr>
<td></td>
<td>BEHAR-COHEN F–Paris</td>
</tr>
<tr>
<td>17:45</td>
<td>Immune responses to gene therapy vectors in the context of corneal transplantation</td>
</tr>
<tr>
<td></td>
<td>RITTER T, WILK M, GONG N, PLEYER U, NOSOV M–Galway, Berlin</td>
</tr>
<tr>
<td>18:00</td>
<td>Regulation of transgene expression</td>
</tr>
<tr>
<td></td>
<td>KOCH P–Brussels</td>
</tr>
<tr>
<td>18:15</td>
<td>Gene therapy for corneal transplantation</td>
</tr>
<tr>
<td></td>
<td>PLEYER U–Berlin</td>
</tr>
<tr>
<td>18:30</td>
<td>Gene therapy: can we prevent/modulate apoptosis in EC?</td>
</tr>
<tr>
<td></td>
<td>FUCHSLUGER T, JURKUNAS U, KAZLAUSKAS A, DANA R–Boston</td>
</tr>
<tr>
<td>18:45</td>
<td>Gene therapy for posterior uveitis</td>
</tr>
<tr>
<td></td>
<td>DICK AD–Bristol</td>
</tr>
</tbody>
</table>
### Ocular blood flow and glaucoma - an update

**Leopold SCHMETTERER**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>19:00</td>
<td>Aging and glaucoma</td>
<td>PILLUNAT L–Dresden</td>
</tr>
<tr>
<td>19:18</td>
<td>AION and glaucoma: similarities and difference</td>
<td>STALMANS I–Leuven</td>
</tr>
<tr>
<td>19:36</td>
<td>Ocular blood flow and visual field preservation?</td>
<td>MARTINEZ-GARCIA A–Santiago de Compostela</td>
</tr>
<tr>
<td>20:00</td>
<td>End of session</td>
<td></td>
</tr>
</tbody>
</table>
**Cornea/Ocular Surface**

**Moderator:** Jean-Jacques GICQUEL, Philippe KESTELYN

301 Lymphocyte and markers of inflammation detection in the conjunctival epithelium of patients with dry eye by enhanced flow cytometry
BARABINO S, MONTALDO E, SOUGHANI F, MINGARI C, ROLANDO M-Gennaro

302 Sutureless and glue free conjunctival autograft in pterygium surgery
DE WIT DW, MOORE J-Cambridge, Belfast

303 Ocular surface findings in patients with congenital aniridia
DE LA PAZ MF, BLANCO Z, ALVAREZ J-Barcelona

304 Compare optical with photometry measures of tear film lipid layer
NEPP J, BENI P, NELL B, SCHAUERBERGER J-Vienna

305 Evaluation of spatial contrast sensitivity after the instillation of diclofenac eye drops
KARAMPATAKIS V, CHATZIMICHAILIS T, KORDALI P, KALPATSANIDIS A, STAMOULAS K-Thessaloniki

306 A pocket slitlamp
ARMOUR R-Stevenage

307 Dextran 70 solutions for the intra-operative control of hydration in rabbit corneas
PENTARIA I, GINS I, DIACOSONIS V, KIMIANSIJOS G, PALLIKARIS IG-Heraklion

308 Simultaneous topo-guided photorefractive keratectomy (PRK) followed by collagen cross-linking (CXL) for the treatment of keratoconus
KONTAKAS GA, KIMIANSIJOS G, PORTALIOU D, KOUNIS G, KARAVITAKI A, PALLIKARIS IG-Heraklion

309 Comparison of morphometric and morphological OCT Visante and UBM potential in anterior segment imaging
MILKA M, WYLEGALA E-Katowice

310 Retinal detachments after Boston keratoprosthesis: incidence, predisposing factors and outcomes of repair
JARDELEZA MS, DODI PL, ZANOTTI C, ROSSI S, ALOE L-Parma, Forli, Rome

311 Prospective evaluation of the Boston keratoprosthesis
AMEND J, SHENSHU J, CHEN J, YAMANOUCHI T, CHEN X, Li Z, PLESIVIC D, HUANG X-Karlsruhe, China, St-Petersburg

312 Cost-effectiveness of the Boston keratoprosthesis
AMEND J, STRJEWIEJSKI TP, DOHLMAN CH-Boston

313 Boston keratoprosthesis with titanium back plate

314 Comparison of deep anterior lamellar keratoplasty results in different TGFß1 corneal dystrophies
NOWINSKA A, WYLEGALA E-Katowice

315 Comparison of the visual response to corneal enhancement on femto-second and microkeratome created raptors
CANADAS SUAREZ P, IBARZ-BARBERA M, HERNANDEZ-VERDEJO J, ARMENTOS I-Madrid

316 Refractive and biomechanical results of intrastromal ring segments for keratoconus
MICHAEL R, SANCHEZ C, MIKLEWICZ M, DE LA PAZ MF, ALVAREZ DE TOLEDO J, BARRAQUER RI-Barcelona

317 Descemet’s membrane detachment diagnosis using a very high frequency ultrasound scanning system (Artelis 2, Ularrink LLC)
STRATOS A, KIMIANSIJOS G, BOUZOUKIS D, KROKIDIS M, TSILIMBARIS M, PALLIKARIS IG-Heraklion

318 Corneal wavefront aberation measured by a rotary scanning system
FRANCO S, OLIVEIRA C, ALMEIDA JB-Baraja

319 Visual fields after refractive surgery
DEMETSTCHA A, GINS I, KIMIANSIJOS G, ASTIRAKAKIS N, PALLIKARIS IG-Heraklion

320 Optical qualities of the Boston keratoprosthesis
SAJTEGH RR, APELA DIAZ L, VARGAS-MARTIN F, WEBB RH, DOHLMAN CH, PELO E-Barcelona

321 Reliability and interobserver variability of non-invasive tear film parameters
KOSINA-HAGYO K, VERES A, FODOR E, LANG ZS, CSAKANY B, NEMETH J-Budapest

322 Ocular Response Analyzer waveforms analysis in normal and post-laser in situ keratomileusis eyes
FRANCO S, FONSECA V, LIRA M-Braga

323 Wavefront analysis in unilateral herpetic keratitis

324 Emergency keratoplasty
VALIYI Z, PEREZ GARCIA D, IBANEZ J, ROJO ARNAO M, MINGUEZ MURO E, CRISTOBAL JA-Zaragoza

325 Corneal biomechanics study: relationship between corneal aberration – hysteresis
PEREZ GARCIA D, IBANEZ J, VALIYI Z, CASAS P, CRISTOBAL JA-Zaragoza

326 Corneal biomechanics study (1): Central corneal thickness versus corneal resistance factor
VALIYI Z, IBANEZ J, PEREZ GARCIA D, JIMENEZ DEL RIO B, CRISTOBAL JA-Zaragoza

327 Tear level of nerve growth factor in normal dogs
DODI PL, ZANOTTI C, ROSSI S, ALOE L-Parma, Forli, Rome

328 Istopathological aspects of complications of DSAEK: our experience
PEICE G, VALENCIANO E, MACNAGHROSSA G, DI GEU L, MONCRONE F-Bari

329 Immune regulatory effect of rapamycin and cyclosporine A on experimental corneal allograft survival

330 Surveillance cultures of contact lenses of patients with Boston KPRO type keratoprosthesis
DE LA CRUZ J, MCMAHON T-Chicago, Illinois

331 Effect of miylocin C on the cicastral corneal response on laser-assisted subepithelial keratectomy to correct myopia
CANADAS SUAREZ P, GARCIA-GONZALEZ M, ARRANZ-MARQUEZ E, TEUS M-Madrid

332 Limbal choristomas – analysis of surgical technique and postoperative results (3 case reports)
ASOKUS R, BLURIE S, JUCCHIA G, MAKSELIS A, PETROSKA D, PAJALUS M-Vienna

333 Crosslinking by riboflavin and UVA. An electron transmission microscopy study in rabbits. Preliminary results
MANGIOSIRIS G, NALTIS K, NIKOLAOUS G, PAPADOPOLIOU DN, KOMENOU A, KAROUITIS A, KARAMPATAKIS V-Thessaloniki

334 LASIK surgery for myopia in Chinese patients
KACHANOV A, BALASHEVICH L, GOLOVATENKO S, TIEHUI Z, WANG X, BAUER S, ZIMIN B-St. Petersburg, Daqing and Harbin

335 Photorefractive keratectomy FAREK in Chinese patients with myopia
KACHANOV A, BALASHEVICH L, GOLOVATENKO S, TIEHUI Z, WANG X, BAUER S, ZIMIN B-St. Petersburg, Daqing and Harbin, St-Petersburg

**Lens/Cataract**

**Moderators:** Jan-Olof KARLSSON, Alfred WEGENER

336 Impact on visual function from light scattering and glintenings in intraocular lenses
MÖNSTAM E, BEHNDIG A–Umeå

337 Coenzyme Q10 prevents human lens epithelial cells from light-induced apoptotic cell-death by reducing oxidative stress and stabilizes BAX/Bcl-2 ratio
KERN T, HINNRENS C, NEUBAUER A.S, ULBIG MW, KAMPIK A–Munich

338 Protective effect of the thioltransferase gene on in vivo UVB-300 nm induced cataract
KRONSCHLÄGER M, YU Z, GAJUCHAIN K, MEYER L, LÖFGREN S, SÖDERBERG PG-Uppsala, Stockholm, Bonn

339 Evaluation of the improvement of sensibility with the new iOL Master software version 5.4.3

340 Aspheric intraocular lenses: effect of residual spherical aberration on objective quality of vision
NOCHEZ Y, FAVARD A, MAIZOUB S, PISELLA R-Tours
**Pathology/Oncology**

**Moderator:** Jan PRAUSE

341 Zone-I retinopathy of prematurity, progression and scheduling of treatment
AKKOYUN I, OTO S, YILMAZ G, TARCAN A, AKOVA AY—Ankara

342 Foveal serous detachment in juvenile idiopathic arthritis (JIA)-associated uveitis

343 A bilateral congenital pits of the optic nerve head. A case report

344 Comparison of spectral-domain and time-domain optical coherence tomography for evaluation of macular thickness and peripapillary retinal nerve fiber layer in multiple sclerosis patients
GARCIA MARTIN E, PUEYO V, PINILLA I, IDOIFE M, GIL ARRIBAS L, FUERTES I, FERNANDEZ J—Zaragoza

345 Rehabilitation treatment of alexia
VILLAFLUERA I, GANGOITI L—Madrid

346 Superior oblique myokymia as a migraine motor aura
KIRK A—Calgary, Alberta

347 Thyroid eye disease and the internet
ZAIY F, JONES C— Maidstone

**Neuro-ophthalmology/Strabismology/ Paediatric Ophthalmology/History of Ophthalmology**

**Moderator:** Aki KAWASAKI

348 Immunohistochemical findings and proliferation markers in uveal melanomas after gamma knife radiosurgery
WACKERNEKEL W, MAYER CF, LACKNER EM, SCHNEIDER MR, LANGMANN G, UNGER F, KLEINERT R—Graz

349 Ophthalmologic outcome of 40 spheno-orbital meningioma resections: 15 years long-term results
BARYLUK A, THALER S, REJDAK R, BOLZ S, ZRENNER E, ZARNOWSKI T—Heraklion

350 Uveal metastasis as initial manifestation of cancer
NOVAK ANDREJIC K, KRAUT A, TEKAVIC POMPE M, JANCAR B—Lubljana

351 IgG4-related sclerosing disease: Is there an association with inflammatory pseudotumours?
HERWIG MC, FISCHER HP, HOLZ FG, LOEFFLER KU—Bonn

352 Orbital and periorbital cystic lesions in Indian children: A retrospective analysis from a tertiary care hospital
SHAMSHINOVA AM, MANSURINA NB, ARAKELYAN MA—Moscow

353 Serious retinal detachment caused by a choroidal metastasis treated with subtenon triamcinolone injection
GOMEZ-TORTUERO E, DIAZ-SERRANO Y, SILLERO-QUINTANA M—Madrid

354 Metastatic cancer presenting with ocular symptoms: a series of cases
PEREZ GARCIA D, TOBENA PUYAL M, VALY J, IBANEZ J, ROJO ARNAO M, JIMENEZ DEL RIO B, CRISTOBAL JA, FERRER A—Zaragoza

355 Comparison of mono- and bicanalicular silicone stent intubation in dacrocystorhinostomy
BELTRAM M, PAJTLER A, DRNOVSEK-OLUP B—Ljubljana

**Vision Sciences/Electrophysiol/ Physiological Optics**

**Moderator:** John BARBUR

356 The effect of a yellow filter on visual performance of older subjects with low macular pigment optical density
PUELL MC, BARRIO AR, PEREZ-CARRASCO MJ, PALOMO C—Madrid

357 Optical filters influence on pupil size according to their material and spectral characteristics

358 Optico-anatomical changes of prematurity children eyes
KRIAUCIUNIENE L, AUKSTKALNIENE R, PAUNKSNIS A—Kaufman

359 How does normal crowding affect visual acuity?
RAUSCHER F, HARLOW A, BARBUR J—London

360 Wavefront map analysis of single vision and progressive ophthalmic lenses
PHUPEAK E, PLAINIS S, PALLIKARIS A, PAPADIAMANTIS A, PALLIKARIS IG—Heraklion

361 The effect of ocular higher order aberrations on contrast sensitivity
GIANNAKOPOULOU T, PLAINIS S, PALLIKARIS A, PALLIKARIS IG—Heraklion

362 Validation of Modified Grating Testing as a visual acuity test in low vision patients with retinitis pigmentosa
THOMAIS A, TAMAIOU S, PALLIKARIS A, PALLIKARIS IG—Heraklion

363 Anterior segment biometrics – investigation of hyperopic eyes with Orbscan
JONUSCHETIS S, DOUGHTY MJ—Glasgow

364 The AGRE instrument applied to visual health: an assessment of the health protocols used in Spain to measure the effects exposure to VDT
SEGUI CRESPO MM, LOPEZ NAVARRO A, RONDA PEREZ E, TASCÓN BERNABEU E, MARTINEZ VERDU FM—Alicante

365 Visual symptomology associated with workers using VDT: a review in the last decade
SEGUI CRESPO MM, LOPEZ NAVARRO A, RONDA PEREZ E—Alicante

366 Electroretinogram alterations in a monozygotic twin sisters discordant for retinitis pigmentosa
HALFELD FURTADO DE MENDONCA R, OLIVEIRA MAIA, JÚNIOR O, HENRIQUE NOVER G, YUKINORO TAKAHASHI W—Sao Paulo

367 The damaging effect of various intensities of light on retinal function in pigmented rats
BARLYUK A, THALER S, REJDAK R, BOLZ S, ZRENNER E, ZARNOWSKI T—Tuebingen, Lublin

368 Analysis of multifocal electroretinography implicit times in the prediction of macular hole formation
VARSANYI B, TUZSON R, NAGY BV, FERENCZI M, FARKAS A—Budapest

369 Morphofunctional changes of macular area in diabetic macular edema
SHAMSHINOVA AM, MANSURINA NB, ARAKELYAN MA—Moscow

370 Development of a software for the exchange of electrophysiological data of vision with PACS: systems based on DICOM
STRASSER T, AVCU S, KONEV V, KORMAZ F, MANAV E, SCHRECK T, TAUKOVIC M, WILKE R, ZRENNER E—Tuebingen, Augsburg
Mark your calendar for the next EVER meeting in Crete

October 6-9, 2010
Saturday
October 3, 2009
### Europa A
**RV: Macular oedema: what is the best treatment?**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>4111 Non surgical approach in diabetic macular edema: the future?</td>
<td>CHIQUET C–Grenoble</td>
</tr>
<tr>
<td>08:33</td>
<td>4112 Which place for surgery for macular edema due to diabetic retinopathy?</td>
<td>JONAS JB–Mannheim</td>
</tr>
<tr>
<td>08:51</td>
<td>4113 Is there still a place for vitrectomy in the treatment of macular edema due to venous occlusion?</td>
<td>POURNARAS CJ–Geneva</td>
</tr>
<tr>
<td>09:09</td>
<td>4114 Macular edema in epiretinal membrane and vitreomacular traction</td>
<td>CREUZOT C–Dijon</td>
</tr>
<tr>
<td>09:27</td>
<td>4115 Macular edema and uveitis: may we find a place for surgery</td>
<td>DE SMET M–Lauzanne</td>
</tr>
</tbody>
</table>

### Europa B
**KPro 1 session: design surgical techniques and complications**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>Welcome by Jean-Marie PAREL</td>
<td></td>
</tr>
<tr>
<td>08:20</td>
<td>Meeting rationale by Giancarlo FALCINELLI</td>
<td></td>
</tr>
<tr>
<td>08:25</td>
<td>4121 History of and necessity for KPros</td>
<td>LIU C, GOMAA A–Brighton, Hove</td>
</tr>
<tr>
<td>08:35</td>
<td>4122 The first keratoprosthesis implantation 1n 1955</td>
<td>DE LA PAZ MF, BARRAQUER J–Barcelona</td>
</tr>
<tr>
<td>08:50</td>
<td>4123 Boston keratoprosthesis</td>
<td>DOHLMAN Ch–Boston</td>
</tr>
<tr>
<td>09:05</td>
<td>4124 Boston type I in pediatric patients</td>
<td>AQUAVELLA J, CHAK G–Rochester</td>
</tr>
<tr>
<td>09:15</td>
<td>4125 Design, surgical technique and complications MOOKP</td>
<td>FALCINELLI GC, COLLARDO P–Rome</td>
</tr>
<tr>
<td>09:25</td>
<td>4126 AlphaCor, Pintucci, Supraderscementic</td>
<td>STOIBER J, HILLE K–Miami</td>
</tr>
<tr>
<td>09:35</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Emerald I
**FRO: Belgian Fund for Research in Ophthalmology**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>4131 Gene transfer of disease regulated promoters during experimental autoimmune uveitis</td>
<td>ELMALEH V–Brussels</td>
</tr>
<tr>
<td>08:45</td>
<td>4133 Investigating the influence of wavelength, light intensity and macular pigmentation on retinal straylight</td>
<td>ROZEMA J–Edegem</td>
</tr>
<tr>
<td>09:00</td>
<td>4134 The effect of microplamin on wound healing after glaucoma filtration surgery</td>
<td>VAN BERGEN T–Leuven</td>
</tr>
<tr>
<td>09:15</td>
<td>4135 Study of the immune response in patients with uveitis and latent tuberculosis</td>
<td>MAKHOUL D–Brussels</td>
</tr>
<tr>
<td>09:30</td>
<td>Questions / Discussion</td>
<td></td>
</tr>
</tbody>
</table>
### FIRST MORNING SESSION

#### Emerald II

**LC: The vision screen in the European mouse clinics**

**08:15 – 09:45**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>4141 The Sanger Institute mouse genetics programme: progress on the high throughput characterisation of knockout mice</td>
<td>GERDIN AK-Hinxton, Cambridgeshire</td>
</tr>
<tr>
<td>08:37</td>
<td>4142 Recent findings and perspectives of the vision screen in the German Mouse Clinic</td>
<td>PUK O, FAVOR J, SUN M, DALKE C, GRAW J-Munich</td>
</tr>
<tr>
<td>08:59</td>
<td>4143 Screening for mouse eye and vision defects at MRC Harwell</td>
<td>MULFORD C, JOYNSON R, CROSS S, WEST K, MCKIE L, JACKSON I-Edinburgh, Oxfordshire</td>
</tr>
<tr>
<td>09:21</td>
<td>4144 Visual phenotyping at the Institut Clinique de la Souris</td>
<td>ROUX M, RIET F, MITTELHAUSER C, MONTIAL M, LECOCQ M, MEZIANE H-Illkirch</td>
</tr>
</tbody>
</table>

#### Mediterranean I

**IM: EVER-SOIE: Progress in quantifying inflammation and monitoring uveitis**

**08:15 – 09:45**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>4151 Precise monitoring of intraocular inflammation by LFP: the gold standard</td>
<td>TUGAL-TUTKUN I-Istanbul</td>
</tr>
<tr>
<td>08:27</td>
<td>4152 Progress in monitoring inflammation in JIA</td>
<td>BODAGHI B-Paris</td>
</tr>
<tr>
<td>08:39</td>
<td>4153 Gain in accuracy for diagnosis and follow-up of uveitis through indocyanine green angiography</td>
<td>HERBORT CP-Lausanne</td>
</tr>
<tr>
<td>08:51</td>
<td>4154 Global angiographic scoring system for inflammatory diseases</td>
<td>KHAIRALLAH M, TUGAL-TUTKUN I, HERBORT CP-Monastir, Istanbul, Lausanne</td>
</tr>
<tr>
<td>09:03</td>
<td>4155 Progress in monitoring inflammatory CMO</td>
<td>DE SMET M-Lausanne</td>
</tr>
<tr>
<td>09:15</td>
<td>4156 Progress in the appraisal and management of inflammatory CNVs</td>
<td>NERI P-Ancona</td>
</tr>
<tr>
<td>09:27</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

#### Adria

**OOG: Protocols 1**

**08:15 – 09:45**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:25</td>
<td>4162 Clinical presentation, pathological features and natural course of metastatic uveal melanoma (MUM) as an orphan and commonly fatal disease</td>
<td>VAN GINDERDEUREN R, CERBONE L, FIEUWs S, VAN EENO L, SPIELEWS W, SCHOFFSKI P-Leuven</td>
</tr>
<tr>
<td>08:45</td>
<td>4164 Cytogenetic profile of locally invasive posterior uveal melanoma</td>
<td>PARROZZANI R, ALEMANY-RUBIO E, PILOTTO E, URBAN F, BONALDI L, MIDENA E-Padova, La Habana</td>
</tr>
<tr>
<td>08:55</td>
<td>4165 Does delayed treatment shorten the life of patients with fatal choroidal melanoma?</td>
<td>DAMATO B, COUPLAND SE-Liverpool</td>
</tr>
<tr>
<td>09:05</td>
<td>4166 An audit of eccentrically-positioned ruthenium plaque radiotherapy of choroidal melanoma in Liverpool</td>
<td>RUSSO A, DAMATO B-Liverpool</td>
</tr>
<tr>
<td>09:15</td>
<td>4167 Primary photodynamic therapy of choroidal melanoma</td>
<td>HEIMANN H, COUPLAND SE, DAMATO B-Liverpool</td>
</tr>
<tr>
<td>09:25</td>
<td>4168 Open-sky biopsy of ciliary body or choroidal tumors of undetermined origin: utility and safety</td>
<td>SCHALENBOURG A, CHAMOT L, UFFER S, ZOGRAFOS L-Lausanne</td>
</tr>
</tbody>
</table>

#### Keynote Lecture 3

**Unravelling the mysteries of ocular lymphomas**

**Sarah COUPLAND - Liverpool, UK**

Introduction by Steffen Heegaard

---

**EVER 2009 programme**
**Europa A**  
**RV: Diabetic retinopathy at a glance**  
11:00 – 12:30

<table>
<thead>
<tr>
<th>Time</th>
<th>FP</th>
<th>Session Title</th>
<th>Authors / Hospitals</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>4211</td>
<td>Semi-automated assessment of microaneurysm formation rate from color fundus photographs in patients with mild NPDR</td>
<td>BERNARDES R, NUNES S, PEREIRA I, LOBO C, CUNHA-VAZ J-Coimbra</td>
</tr>
<tr>
<td>11:12</td>
<td>4212</td>
<td>Validation of a predictive model for diabetic retinopathy progression in type-2 diabetic patients with mild nonproliferative diabetic retinopathy.</td>
<td>NUNES S, BERNARDES R, LOBO C, CUNHA-VAZ J-Coimbra</td>
</tr>
<tr>
<td>11:24</td>
<td>4213</td>
<td>Retinal hemodynamic changes in diabetic macular edema</td>
<td>HUDSON C, GUAN K, LAM WC, MANDELCORN M, DEVENYI RG, FLANAGAN JG-Toronto</td>
</tr>
<tr>
<td>11:36</td>
<td>4214</td>
<td>Long-term result of intravitreal steroid for macular oedema: 2 to 5 year follow-up of 92 eyes</td>
<td>ZAIDI F, ANSARI E-Maidstone</td>
</tr>
<tr>
<td>11:42</td>
<td>4215</td>
<td>The relationship between retinal hemodynamics and systemic markers of endothelial function and inflammation in type 2 diabetes</td>
<td>HUDSON C, KHIU LA, PALKA E, FLANAGAN JG, WONG T, LAM WC, MARKOWITZ SN, BRENT M, MANDELCORN M, DEVENYI RG-Toronto</td>
</tr>
<tr>
<td>11:48</td>
<td>4216</td>
<td>Assessment of retinal arteriolar hemodynamics in patients pre- and post-cataract extraction</td>
<td>HUDSON C, AZIZI B, WONG T, SINGER S-Toronto, Waterloo</td>
</tr>
<tr>
<td>11:54</td>
<td>4217</td>
<td>Effects of conventional argon panretinal laser photocoagulation on retinal nerve fibre layer and driving visual fields in diabetic retinopathy</td>
<td>MUQUIT MMK, GHANCHI FD, WAKELY L, HENSON DB, STANGA PE-Manchester, Bradford</td>
</tr>
</tbody>
</table>

**Europa B**  
**KPro 2 session: Clinical results and indications**  
11:00 – 12:30

<table>
<thead>
<tr>
<th>Time</th>
<th>FP</th>
<th>Session Title</th>
<th>Authors / Hospitals</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>4221</td>
<td>How should we quantify the performance of KPro’s? VATI</td>
<td>GRABNER G, STOIBER J, HITZL W-Salzburg</td>
</tr>
<tr>
<td>11:10</td>
<td>4222</td>
<td>The Boston keratoprosthesis in autoimmune disease</td>
<td>CHODOSH J-Boston</td>
</tr>
<tr>
<td>11:22</td>
<td>4223</td>
<td>Boston keratoprosthesis in pediatric patients</td>
<td>AQUAVELLA J</td>
</tr>
<tr>
<td>11:32</td>
<td>4224</td>
<td>Long-term functional and anatomical results of OOKP and tibial OKP: Barcelona experience</td>
<td>DE LA PAZ MF, BARRAQUER J-Barcelona</td>
</tr>
<tr>
<td>11:42</td>
<td>4225</td>
<td>Tibial KPro</td>
<td>TEMPRANO J-Barcelona</td>
</tr>
<tr>
<td>11:50</td>
<td>4226</td>
<td>MOOKP clinical results and Indications</td>
<td>FALCINELLI G-Rome</td>
</tr>
<tr>
<td>12:00</td>
<td>4227</td>
<td>AlphaCor, Pintucci, Suprascemetic</td>
<td>PROSDOCIMO G-Coniglio</td>
</tr>
<tr>
<td>12:10</td>
<td>4228</td>
<td>Clinical decision paths in KPro Surgery</td>
<td>GRABNER G, STOIBER J, HITZL W-Salzburg</td>
</tr>
<tr>
<td>12:20</td>
<td></td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

**Emerald I**  
**FRO: Belgian Fund for Research in Ophthalmology 2**  
11:00 – 12:30

<table>
<thead>
<tr>
<th>Time</th>
<th>FP</th>
<th>Session Title</th>
<th>Authors / Hospitals</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>4231</td>
<td>Safety evaluation of intravitreal use of a beta2-agonist in rabbit eyes</td>
<td>VAN CALSTER J, VERSTRAETEN S, STALMANS P-Leuven</td>
</tr>
<tr>
<td>11:15</td>
<td>4232</td>
<td>The role of lox and LOXL2 in inflammation and fibrosis in a laser induced mouse model</td>
<td>VAN DE VEIRE S-Leuven</td>
</tr>
<tr>
<td>11:30</td>
<td>4233</td>
<td>Can preoperative bevacizumab improve trabeculectomy outcome? Avastin-Trab study</td>
<td>VANDEWALLE E-Leuven</td>
</tr>
<tr>
<td>11:45</td>
<td>4234</td>
<td>Is neuroglobin (Ngb) a perspective for glaucoma?</td>
<td>YOU Y-Leuven</td>
</tr>
<tr>
<td>12:00</td>
<td>4235</td>
<td>Immunomodulation of corneal epithelial cells following electroporation with mRNA encoding IL-10 and FasL</td>
<td>ZAKARIA N-Antwerp</td>
</tr>
<tr>
<td>12:15</td>
<td></td>
<td>Questions / Discussion</td>
<td></td>
</tr>
<tr>
<td>Emerald II</td>
<td><strong>LC:</strong> Microincision cataract surgery (MICS). is smaller better?</td>
<td>11:00 – 12:30</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>---------------------------------------------------------------</td>
<td>----------------</td>
<td></td>
</tr>
<tr>
<td>SIS</td>
<td>Alain BRON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>4241 Fundamentals of cataract development</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>WEGENER A–Bonn</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:18</td>
<td>4242 Micro-incision (MICS), perfecting wound incision</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>COCHENER B–Brest</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:36</td>
<td>4243 MICS, mastering the critical steps</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BELLUCCI R</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:54</td>
<td>4244 MICS and vitreo retinal surgeries</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CREUZOT C–Dijon</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:12</td>
<td>4245 MICS and glaucoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BRON AM–Dijon</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mediterranea I</th>
<th><strong>IM:</strong> Anti-infectives: from research to clinic</th>
<th>11:00 – 12:30</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIS</td>
<td>Regis KOWALSKI, Eric ROMANOWSKI</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>4251 Prophylaxis of posttraumatic endophthalmitis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ABU EL ASRAR A–Riyadh</td>
<td></td>
</tr>
<tr>
<td>11:18</td>
<td>4252 Animal studies for the prevention of endophthalmitis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>KOWALSKI RP–Pittsburgh</td>
<td></td>
</tr>
<tr>
<td>11:36</td>
<td>4253 Bacterial keratitis: the clinical problem</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PLEYER U–Berlin</td>
<td></td>
</tr>
<tr>
<td>11:54</td>
<td>4254 Animal models for the treatment of bacterial keratitis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>KOWALSKI RP–Pittsburgh</td>
<td></td>
</tr>
<tr>
<td>12:12</td>
<td>4255 The use of animal models for the evaluation of ocular antiviral agents</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ROMANOWSKI EG–Pittsburgh</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adria</th>
<th><strong>PO:</strong> Radiotherapy in ophthalmic oncology</th>
<th>11:00 – 12:30</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIS</td>
<td>Laurence DESJARDINS, Bertil DAMATO</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>4261 Basic principles of radiotherapy in ophthalmic oncology</td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td>4262 The treatment of uveal melanoma by ruthenium plaques</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DAMATO B–Liverpool</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>4263 18 years experience of the use of proton beam in ophthalmic tumours</td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td>4264 Limiting the sequelae of irradiation in retinoblastoma patients by using globe and orbital brachytherapy with iodine 125</td>
<td></td>
</tr>
<tr>
<td></td>
<td>STANNARD C</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>4265 The use of ruthenium plaque brachytherapy in retinoblastoma</td>
<td></td>
</tr>
<tr>
<td>12:15</td>
<td>4266 The treatment of uveal melanoma with iodine plaque brachytherapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>KIVELÅ T–Helsinki</td>
<td></td>
</tr>
</tbody>
</table>

*EVER 2009 programme*
<table>
<thead>
<tr>
<th>Role of Inflammation in RVO</th>
<th>12:35 – 13:35</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gisèle SOUBRANE, Constantin POURNARAS</strong></td>
<td></td>
</tr>
</tbody>
</table>
| 12:35 | Macular edema and RVO. Role of inflammation  
POURNARAS CJ–Geneva |
| 12:50 | Use of steroids in Macular Edema, are all the steroids the same?  
DE SMET M–Lausanne |
| 13:05 | New developments in treating Macular Edema, Posurdex RVO Phase III results  
SOUBRANE S–Créteil |
| 13:20 | Macular edema – With all the new data (BRAVO, SCORE and Posurdex) where to from here?  
DE SMET M–Lausanne |
| 13:35 | End of session |
### Europa A: RV: New ocular imaging in retinopathies

**SIS**

**Gisèle SOUBRANE**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45</td>
<td>4311</td>
<td>Principle of adaptive optics</td>
<td>SÖDERBERG PG–Uppsala</td>
</tr>
<tr>
<td>14:00</td>
<td>4312</td>
<td>Telangiectasia evaluated with adaptive optics and HR-OCT</td>
<td>ATMANI K, LEVEZIEL N, SOUBRANE G–Creteil</td>
</tr>
<tr>
<td>14:15</td>
<td>4313</td>
<td>Spectral domain OCT of exudative AMD</td>
<td>LEVEZIEL N, VOIGT M, COSCAS G, SOUBRANE G–Creteil</td>
</tr>
<tr>
<td>14:30</td>
<td>4314</td>
<td>Drusen in adaptive optics and SD-OCT</td>
<td>MASSAMBA N, LAMORY B, SOUBRANE G–Creteil, Orsay</td>
</tr>
<tr>
<td>14:45</td>
<td>4315</td>
<td>Chorioretinal anastomosis in adaptive optic and high definition spectral domain optical coherence tomography</td>
<td>MAILLON C, VOIGT M, COSCAS G, SOUBRANE G–Creteil</td>
</tr>
<tr>
<td>15:00</td>
<td>4316</td>
<td>Perspective for adaptive optics</td>
<td>CHATEAU N, LAMORY B–Orsay</td>
</tr>
</tbody>
</table>

### Europa B: KPro 3 session

**Joint M.**

**Joaquin BARRAQUER, Giancarlo FALCINELLI, Jean Marie PAREL**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45</td>
<td>4321</td>
<td>Running a clinical service for KPros</td>
<td>BARATZ K</td>
</tr>
<tr>
<td>13:55</td>
<td>4322</td>
<td>How do we get started with offering MOOKP clinical service?</td>
<td>FUKUDA M, HAMADA S, LIU C–Osaka, Brighton</td>
</tr>
<tr>
<td>14:05</td>
<td>4323</td>
<td>Why we never use a KPro and MOOKP</td>
<td>KINOSHITA SS–Kyoto</td>
</tr>
<tr>
<td>14:15</td>
<td>4324</td>
<td>Inflammatory responses to KPro: can we control them?</td>
<td>PEREZ VS–Miami</td>
</tr>
<tr>
<td>14:25</td>
<td>4325</td>
<td>Retinal detachment in Falcinelli’s modified osteoodontokeratoprosthesis</td>
<td>COLLUARDO P, FALCINELLI G–Rome</td>
</tr>
<tr>
<td>14:35</td>
<td>4326</td>
<td>Tibial Bone KPro technique and long term results</td>
<td>TEMPRANO J–Barcelona</td>
</tr>
<tr>
<td>14:45</td>
<td>4327</td>
<td>Management of oculoplastic problems in the OOKP eye</td>
<td>GOMAA A, MORRIS P, BRITAIN P, HEROLD J, THORP S, LIU C–Brighton</td>
</tr>
<tr>
<td>14:55</td>
<td>4328</td>
<td>Dealing with complications of MOOKP: VR</td>
<td>HUGHES E–Bristol</td>
</tr>
<tr>
<td>15:05</td>
<td></td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Emerald I: ACB: Cell biology of the retina

**FP Richard BRUENECH, Kai KAARNIRANTA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45</td>
<td>4331</td>
<td>Quantification of neuronal cells in healthy rat retinas by flow cytometry</td>
<td>TSOKA P, PAPADAKI E, PALLIKARIOS IG, TSILIMBARIS M–Heraklion</td>
</tr>
<tr>
<td>13:57</td>
<td>4332</td>
<td>Clearance of dying cells in the retina - relevance to age-related macula degeneration</td>
<td>PETROVSKI G, BERENYI E, VAJAS A, FESUS L, FACSko A, BERTA A–Debrecen</td>
</tr>
<tr>
<td>14:09</td>
<td>4333</td>
<td>Role of HSP70 and p62 in regulation of autophagy clearance in ARPE-19 cells</td>
<td>KAARNIRANTA K–Kuopio</td>
</tr>
<tr>
<td>14:45</td>
<td>4336</td>
<td>Relationship between VEGF expression and the retina following light-damage</td>
<td>CACHAFEIRO M, BEMELMANS AP, WENZEL A, ARSENIJEVIC Y–Lausanne, Zurich</td>
</tr>
</tbody>
</table>

### Poster session 3

**Immunology/Microbiology - Retina/Vitreous**

**Friederike MACKENSEN, François WILLERMAIN, Constantin POURNARAS, Charles RIVA**

**Posters on pages 60-61**
**Emerald II**  
**ARVO Session: Finding a US Postdoctoral Fellow Position**  
**Joint M. Sally ATHERTON**

13:45 – 15:15

Essential for anyone considering a US fellowship.

Helpful advice on finding the best location, mentor and financial arrangements for a rewarding experience will be presented. Lore Anne McNichol, PhD, Deputy Director of the National Eye Institute, will discuss how to apply for an NIH/NEI postdoctoral position. Sally Atherton, PhD of the Medical College of Georgia, will cover the opportunities in universities and what is needed regarding visas and how to make the system provide the experience that you want. Marzena Gajecka, PhD of the Polish Academy of Sciences will speak about her experience at Washington State University. Ample time for questions and answers.

---

**Mediterranea I**  
**IM: Trends in ocular immunology and microbiology research**  
**Joint M. Sarah COUPLAND**

13:45 – 15:15

<table>
<thead>
<tr>
<th>FP</th>
<th>Name</th>
<th>Title</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45</td>
<td>Philippe KOCH, Regis KOWALSKI</td>
<td>Circulating bone marrow-derived endothelial precursor cells contribute to neovascularization in diabetic epiretinal membranes ABU EL ASRAR A, STRUYF S, VERBEKE H, VAN DAMME J, GEBOES K–Riyadh, Leuven</td>
<td>4351</td>
</tr>
<tr>
<td>14:09</td>
<td></td>
<td>Experience with adalimumab for the treatment of non-infectious uveitis DOBNER B–Heidelberg</td>
<td>4353</td>
</tr>
<tr>
<td>14:33</td>
<td></td>
<td>Ophthalmic microsporidiosis: the Manchester experience BONSHEK R, CURRY A, IRION L–Manchester</td>
<td>4355</td>
</tr>
<tr>
<td>14:45</td>
<td></td>
<td>Topical levofloxacin 1.5% is effective in reducing levofloxacin-resistant MRSA and FQ-resistant pseudomonas aeruginosa in keratitis models KOWALSKI RP, ROMANOWSKI EG, MAH FS, SHANKS RMQ, GORDON YJ–Pittsburgh</td>
<td>4356</td>
</tr>
<tr>
<td>14:51</td>
<td></td>
<td>TNFα suppresses IFNγ-induced MHC Class II expression in retinal pigmented epithelial cells by down regulating Class II trans-activator mRNA MAKHOUIL M, BRUYN S, KOCH P, CAPERS L, WILLERMAIN F–Bruxelles</td>
<td>4357</td>
</tr>
<tr>
<td>14:57</td>
<td></td>
<td>In vitro antimicrobial effect of vitreous endotamponading substances MONTERO MORENO JA, SANCHIS MERINO ME, RUIZ-MORENO JM–Valadolid, Albacete</td>
<td>4358</td>
</tr>
<tr>
<td>15:03</td>
<td></td>
<td>An epidemiologic analysis of staphylococcus aureus-associated keratitis in Boston BEHLAU I, HEIMER SR, LEONARD EM, MARTIN JN, DOHLMAN CH, GILMORE MS–Boston</td>
<td>4359</td>
</tr>
<tr>
<td>15:09</td>
<td></td>
<td>Comparative assessment of S. aureus microbial biofilm inhibition by an N-alkyl-polyethyleneimine covalently attached to PMMA or titanium in the Boston Keratoprosthesis BEHLAU I, MUKHERJEE K, TODANI A, KLIBANOV AM, GILMORE MS, DOHLMAN CH–Boston, Cambridge</td>
<td>435a</td>
</tr>
</tbody>
</table>

---

**Adria**  
**OOG: Protocols 2**  
**Joint M. Sarah COUPLAND**

13:45 – 15:15

<table>
<thead>
<tr>
<th>FP</th>
<th>Name</th>
<th>Title</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45</td>
<td></td>
<td>Pigmented eyelid lesion - unexpected findings LOEFFLER KU–Bonn</td>
<td>4361</td>
</tr>
<tr>
<td>14:05</td>
<td></td>
<td>Irido-cilio-choroidal melanoma in a 5-year old child PETER J–Jerusalem</td>
<td>4363</td>
</tr>
<tr>
<td>14:15</td>
<td></td>
<td>A child with a melanocytic ciliary body tumour KIVELÄ T–Helsinki</td>
<td>4364</td>
</tr>
<tr>
<td>14:25</td>
<td></td>
<td>Local resection of end-stage choroidal melanoma DAMATO B–Liverpool</td>
<td>4365</td>
</tr>
<tr>
<td>14:35</td>
<td></td>
<td>Large retinal hemangioma treated in second hand by betabraclytherapy, on a single eye of a young adult GRANGE JD, KODJIKIAN L–Lyon</td>
<td>4366</td>
</tr>
<tr>
<td>14:45</td>
<td></td>
<td>Sudden loss of vision 15 years after renal transplantation COUPLAND SE, THUMANN G–Liverpool</td>
<td>4367</td>
</tr>
<tr>
<td>14:55</td>
<td></td>
<td>Orbital mantle cell lymphoma BRISCOE D–Kfar Saba</td>
<td>4368</td>
</tr>
</tbody>
</table>
### Europa A — EVER General Assembly and Prize Giving

#### Agenda
1. President’s address
3. Report of the General Secretary
4. Report of the Programme Secretary
5. Report of the Treasurer, approval of the accounts 2008, discharge to the directors, budget for 2009
6. Results of the elections
7. Announcement of the replacement of the Chair of the Pathology/Oncology Section
8. Acta Board members
9. Presentation of the board 2009-2010
10. President Elect, Vice President Elect
11. Presentation and Report of the Scientific Sections meetings
12. Future congresses
13. Prize giving
14. Miscellanea

#### Europa A

**RV: Choroidal blood flow in the healthy and diseased eye**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors and Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:45</td>
<td>SIS</td>
<td>Complex regulation of choroidal blood flow during combined changes in blood pressure and IOP</td>
<td>Schmetterer L—Vienna, Chiquest C, Geisler MH—Grenoble, Sion</td>
</tr>
<tr>
<td>17:45</td>
<td>4411</td>
<td>Evaluation of choroidal blood flow after treatment of retinal diseases</td>
<td>Chiquest C, Geisler MH—Grenoble, Sion</td>
</tr>
<tr>
<td>17:45</td>
<td>4412</td>
<td>Age-related macular degeneration: hemodynamic changes</td>
<td>Pournaras CJ, Pournaras JAC, Mendrinos E—Geneva, Lausanne</td>
</tr>
<tr>
<td>17:45</td>
<td>4413</td>
<td>Subfoveal choroidal blood flow and central retinal function in retinitis pigmentosa</td>
<td>Falsini B—Rome</td>
</tr>
<tr>
<td>17:45</td>
<td>4414</td>
<td>Autoregulation in the choroid</td>
<td>Orgul S—Basel</td>
</tr>
</tbody>
</table>

### Europa B — KPro 4 session

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors and Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:45</td>
<td>Joint M.</td>
<td>Biosynthetic corneas – evaluation in humans</td>
<td>Fagerholm P, Lagali N, Griffith M—Linköping, Ontario</td>
</tr>
<tr>
<td>17:45</td>
<td>4421</td>
<td>Keratoprosthesis surgery: Eastern European and Russian devices</td>
<td>Zagorski ZF, Yakimienko S, Moroz Z—Lublin, Odessa, Moscow</td>
</tr>
<tr>
<td>17:45</td>
<td>4422</td>
<td>Glaucoma associated with KPros</td>
<td>Hille K—Offenburg</td>
</tr>
<tr>
<td>17:45</td>
<td>4425</td>
<td>Glaucoma treatment in MOOKP</td>
<td>Taloni M, Falcinelli G</td>
</tr>
<tr>
<td>17:45</td>
<td>4429</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
Emerald I
Workshop
**IM: How to get your work published ?**
Uwe PLEYER

Junior researchers often face the challenge of getting their interesting work published. The goal of this course will be to provide some keys to write a high quality paper that will help to transform innovative ideas into a research article. The panelists will discuss major aspects of the editorial process including basic decisions: where to submit the work, how to organize and prepare a manuscript, how to deal the review process in particular the revision process for eventual resubmission. The panelists will raise the discussion on issues like:
- How to choose a journal?
- How to organize your paper?
- What are the characteristics of a good manuscript?
- Delayed response: When is it appropriate to ask for the status of your manuscript?
- How to interpret the letter from the editor?
- How to write a good reply to the reviewers?
- What to do when your paper is rejected?
- When can it be appropriate to request a reevaluation of a rejected paper?

In addition, the personal view from an author and editor’s perspective will be given in a vivid discussion with the participants.

Panel: Pinar Aydin, Harminder Dua, Jochen Graw, Uwe Pleyer

Mediterranea I
**IM: Ocular inflammation and infection: new agents and newly recognised inflammatory disease patterns**
SIS
Moncef KHAIRALLAH, Carl P HERBORT

17:45 4451 Introduction by Carl HERBORT
18:00 4452 Emerging and poorly known viral inflammatory eye diseases
KHAIRALLAH M–Monastir
18:15 4453 Uveitis caused by fastidious bacteria
BODAGHI B, DRANCOURT M, CASSOUX N, RAOULT D, LEHOANG P–Marseille, Paris
18:30 4454 Serpiginous choroiditis revisited
MACKENSEN F–Heidelberg
18:45 4455 Appraisal and management of subclinical choroidal inflammation: the iceberg phenomenon
HERBORT CP–Lausanne
19:00 4456 Significance of autofluorescence in choriocapillaritis
MANTOVANI A, HERBORT CP–Como, Lausanne

Adria
**OOG: Business Meeting**
Sarah COUPLAND

1. Matters arising from the Minutes
2. Nominations for OOG Membership
3. OOG Website update
4. Trial Proposals and Updates:
   - Tero Kivela: Intravitreal salvage chemotherapy for retinoblastoma after chemoreduction
   - Bertil Damato: Non-treatment of uveal melanomas – new proposal
   - Bertil Damato: Update on conjunctival melanoma study
   - Martine Jager: TORR update
5. Any Other Business (AOB):
6. Future Meeting details:
   - Liverpool/Wales – March 19th-21st, 2010
   - EVER/OOG - Crete Oct 6-9, 2010

Social
20:00 - 23:00 in S. Bernardin
**EVER Farewell dinner with musical entertainment**

EVER 2009 programme
Immunology/Microbiology

Moderators: Friederike MACKENSEN, François WILLERMAIN

401 Topical levofloxacin 1.5% is effective in reducing levofloxacin-resistant MRSA and MRQ-resistant pseudomonas aerugiosa in keratitis models
KOWALSKI KP, ROMANOWSKI EG, MAH FS, SHANKS RMQ, GORDON YJ–Pittsburgh

402 TNFα suppresses IFNγ-induced MHCI expression in retinal pigmented epithelial cells by down regulating Class II trans-activator mRNA
MAKHOUL M, BRUNYS C, KOCH P, CASPERS L, WILLERMAIN F–Bruxelles

403 In vitro antimicrobial effect of vitreous endotamponading substances
MONTERO MORENO JA, SANCHIS MERINO ME, RUIZ-MORENO JM–Valladolid, Albacete

404 An epidemiologic analysis of Staphylococcus aureus-associated keratitis in Boston
BEHLAU J, HEIMER SR, LEONARD EM, MARTIN JN, DOHLMAN CH, GILMORE MS–Boston

405 Comparative assessment of S. aureus microbial biofilm inhibition by an N-alkyl-polyethyleneimine covalently attached to PMMA or titanium in the Boston keratoprosthesis
BEHLAU J, MUKHERJEE K, TODANI A, KUBANOV AM, GILMORE MS, DOHLMAN CH–Boston, Cambridge

406 Three years experience of QuantiFERON® Gold testing
JAKOB E, MACKENSEN F, BECKER MD, MAX R, DALPKE A, ZIMMERMANN S–Heidelberg, Zürich

407 Implantation of intraocular lens in children with uveitis: long term visual outcome and prognosis

408 Aqueous humor heparin-binding epidermal growth factor-like levels in patients with acute uveitis

409 Aqueous humor keratinocyte growth factor levels in patients with acute anterior uveitis

410 A case of intraocular drofolia in a dog: alarm bell for human beings?
DODI PL, ZANOTTI C–Parma, Forli

411 Inhibition of viral replication in vitro by antiviral-treated amniotic membrane
MENCUCCI R, PALADINI I, MENCHINI U, DEI R–Riflessor

412 Ultrastructure of anterior lens capsule in uveitic cataract
STUNF S, HVALA A, VIDOVIC VALENTINCIC N, KRAUT A, HAWLINA M–Ljubljana

413 Wiskott-Aldrich syndrome: A case with scleritis
KARAMPATAKIS V, KORDALI P, KARAHWAYS B–Thessaloniki

414 The role of VEGF in intermediate uveitis patients
VIDOVIC VALENTINCIC N, KRAUT A, KOSICEK P, HAWLINA M, ROTHOVA A–Ljubljana, Golnik, Utrecht

415 Intracameral amphotericin B in the management of Candida glabrata anterior uveitis after penetrating keratoplasty
SCHOLLNER P, KRAUT A, GLOBOCNIK-PETROVIC M, PFEIFER V–Ljubljana

416 Diffusion tensor magnetic resonance imaging and fiber tracking of trigeminal nerves in relapsing herpetic keratouveitis

417 Presence of QuantiFERON®-TB (QT) Gold test (Cellestis) in patients with positive Tuberculin Skin Test (TST) in etiological and therapeutic work-up in uveitis

418 Ocular hypertension and uveitis: about 103 cases of uveitis

Retina/Vitreous

Moderators: Constantin POURNARAS, Charles RIVA

419 Outcome following ranibizumab therapy for neovascular age related macular degeneration in patients with poor, intermediate and good vision
ADEPEGBA O, OYOMI S, GUPTA B, SIVAPRAVASAD S–London

420 Wet AMD treatment with ranibizumab - structural and functional changes during treatment
RADECKA L, LAGANOVA S–Riga

421 Anti-VEGF therapy and influence of vitreomacular traction in wet AMD
CORTES MORA N, LOPEZ GALVEZ M, MANZANAS LEAL L, RODRIGUEZ DE LA RUA FRANCO E, GILARDO ARGUELLO A–Valladolid

422 Evaluation and inter-observer analysis of retinography existing clinical classification system to categorize moderate retinopathies
SANCHEZ RAMOS C, WASSF M, BONNIN-ARIAS C, VINAS-PENA M, FORLAN A, MOLINA-GOMEZ M, CHAMORRO E–Madrid

423 Intravitreal bevacizumab for neovascular age-related macular degeneration: twelve months of follow up
EL MATRI L, BACOUTI K, BOURRAOUI R, KORT F, LIMAEM R, BEN YESSEF N, LANDOULI H–Tunis

424 Retinal pigment epithelial tears following administration of intravitreal bevacizumab (3 case reports)
KOWALSKI RP, ROMANOWSKI EG, MAH FS, SHANKS RMQ, GORDON YJ–Boston

425 Retinal angiomatous proliferation: is intravitreal ranibizumab therapy enough?
MARJANOVIC B, GEORGOUIS P, MANDAL K, PATRA S–Bristol

426 Combined 23-gauge sutureless pars plana vitrectomy (ppV), injection of recombined tissue plasminogen activator (rtPA), expansile gas and bevacizumab treating acute subretinal haemorrhage (SRH) in exsudative AMD
MAIER M, PERZ C, FEULICH N, KONRAD J, WINKLER VON MOHRNFELS C, LOHMANN CP–Munich

427 Apoptotic activity of intravitreal bevacizumab on rabbit retina
TURCU MF, ALPHN TN, KURCCU G, KULACOGLU S, KURAL G–Ankara

428 Intravitreal bevacizumab as primary local treatment for choroidal neovascularization secondary to uveitis
JULIAN K, FARDEAU C, TERRADA C, FRANCAIS C, LEHOANG P, BODAGHI B–Paris

429 Photodynamic therapy for symptomatic circumscribed choroidal hemangioma
MAYER CF, WACKERNAGEL W, LACKNER EM, SCHNEIDER MR, HAAS A, WEGER M, LANGMANN G–Graz

430 Comparison of corneal thickness, anterior segment depth and pupil diameter between patients with neovascular age-related macular degeneration and controls
PAHOR D, KNEZ N, SIKKO K–Maribor

431 Repeatability in the measurement of macular optical density using the Metropsis Test
PEREZ CARRASCO MJ, BARRIO AR, PALOMO C, PUELL MC–Madrid

432 Comparison of macular pigment optical density (MPOD) between a northern European and a Mediterranean population
TSKA C, MAKRIDAKI M, PLAINS S, TSLIMBARIAS M, PALLIKARIAS IG–Heraklion, Manchester

433 Verteporfin encapsulated in cationic liposomes as an alternative drug for PDT
RANBAR M, MARTIN G, AGOSTINI HT–Freiburg

434 Effects of photodynamic therapy on retinal vessels in the mouse model of laser-induced choroidal neovascularization
EVERS C, RANBAR M, GROSS NJ, MARTIN G, AGOSTINI HT–Freiburg

435 Intravitreal bevacizumab for choroidal neovascularization secondary to angiod streaks: one year follow-up

436 Macular edema and neovascularization in a case of Stargardt macular dystrophy
KARAMPATAKIS V, VOUTAS S, LAKE S, KORDALI P–Thessaloniki
437 Some questions of immune response to retinal S-antigen and development of myopia’s complications
LÁZUK AV, SLEPOVA OS-Tula, Moscow

438 Treatment of neovascularization myopic with ranibizumab: 18-month results
EGEA ESTOPINAN MC, TORRON FERNANDEZ-BLANCO C, GUERRI MONCLUS N, PRIETO CALVO E, FERRER NOVELLA E, RUÍZ MORENO O, PABLO LE-Zaragoza

439 Bevacizumab and ranibizumab treatments for neovascularization from causes other than age-related macular degeneration
AZIZ S, BANERJEE S-Leicester

440 Comparison of spectral-domain cirrus optical coherence tomography (OCT) and time-domain Stratus OCT for the evaluation of macular and peripapillary retinal nerve fiber layer thickness in patients with diabetes type 2
GIL ARRIAS L, GARCIA MARTIN E, IDOPE M, FUERTES I, PINILLA I-Zaragoza

441 Differences in macular thickness studied by time domain optical coherence tomography (OCT) and spectral domain OCT in healthy subjects
IDOPE M, GIL ARRIAS L, PINILLA I, GARCIA MARTIN E, FUERTES LAZARO M-Zaragoza

442 Comparison of Spectralis Fourier-domain optical coherence tomography (OCT) and time-domain Stratus OCT for the evaluation of macular thickness in patients with diabetes mellitus type 2
GIL ARRIAS L, IDOPE M, GARCIA MARTIN E, PINILLA I, FUERTES LAZARO M-Zaragoza

443 Comparison of the peripapillary retinal nerve fiber layer thickness in healthy subjects measured by spectral-domain Cirrus optical coherence tomography and time-domain Stratus optical coherence tomography
FUERTES I, PINILLA I, GARCIA MARTIN E, GIL ARRIAS L, IDOPE M, CALVO PEREZ P-Zaragoza

444 Repeatability of retinal nerve fiber layer and macular thickness measurements using Cirrus Fourier-domain optical coherence
GARCIA MARTIN E, PINILLA I, IDOPE M, GIL ARRIAS L, FUERTES I, PUEYO V-Zaragoza

445 Comparison of spectral-domain Cirrus optical coherence tomography and time-domain Stratus optical coherence tomography for the evaluation of macular thickness in healthy subjects
FUERTES I, PINILLA I, GARCIA MARTIN E, IDOPE M, GIL ARRIAS L-Zaragoza

446 Retinal nerve fiber layer and macular thickness measured with Cirrus and Spectralis Fourier-domain optical coherence tomographies: comparative study in healthy eyes
PINILLA I, GARCIA MARTIN E, IDOPE M, GIL ARRIAS L, FUERTES M, FERRERAS A-Zaragoza

447 Clinically useful wide-field high-resolution retinal imaging optics with a dual-conjugate adaptive instrument
SJÖSTRAND J, KNUTSSON P, POPOVIC Z, THAUNG J-Gothenburg

448 Optical coherence tomography and biomicroscopic analysis in macular holes
FRUSCHELLI M, MOTOLESE I, MOTOLESE PA, FAIREZOTTI P, MOTOLESE E-Siena, Grosseto

449 Local and genetic determinants of retinal vascular endothelial growth factor in vision threatening proliferative diabetic retinopathy
GLOBOCNIK PETROVIC M, HAWLINA M, KOSNIK M, ROHSEK P, PETROVIC D-Ljubljana, Golnik

450 Intravitreal combination of triamcinolone acetonide – bevacizumab (Kenacort–Avastin) in diabetic macular edema
ELEFtheriadou M, FRAGKISKOU S, PANTELEINtIS V, PAPADAKI T, TSLIMBARI M, PALLIKARIS IG–Heraklion

451 Visual function vs quality of life assessment in patients with laser-treated diabetic macular edema
PEARCE L, SIVAPRASAD S, CHONG V-London, Oxford

452 Use of the contrast sensitivity in the diagnosis of diabetic retinopathy and diabetic macular edema
IBANEZ J, VALYI Z, PEREZ GARCIA D, PEIRO C, CRISTOBAL JA, FAURE E, SAINZ A-Zaragoza

453 Use of retinal photography in the diagnosis of clinically significant macular edema (CME)

454 Ocular and systemic endothelial function in the offspring of diabetics: a pilot study

455 Long-term result of intravitreal steroid for macular oedema: 2-10 year follow-up of 92 eyes
ZAIDI F, ANSARI E-Maidstone

456 The relationship between retinal hemodynamics and systemic markers of endothelial function and inflammation in type 2 diabetes
HUDSON C, KHUH LA, PALKA E, FLANAGAN JG, WONG T, IAM WC, MARKWITZ SN, BRENT M, MANDELCCORN M, DEVENYRI RG-Toronto

457 Assessment of retinal arteriolar hemodynamics in patients pre- and post-cataract extraction
HUDSON C, AZIZI B, WANG J, WONG T, SINGER S–Toronto, Waterloo

458 Effects of conventional argon panretinal laser photocoagulation on retinal nerve fibre layer and driving visual fields in diabetic retinopathy
MUQIT MMK, GHANCHI FD, WAKELY L, HENSON DB, STANGA PE-Manchester, Bradford

459 Efficacy after intravitreal bevacizumab and triamcinolone injection in BRVO patients
CHOI M, LEW Y-Seoul

460 Bilateral central serous chorioretinopathy in a patient with focal segmental glomerulosclerosis
PRIETO CALVO E, EGEA ESTOPINAN MC, GUERRI MONCLUS N, RUÍZ MORENO O-Zaragoza

461 Internal limiting membrane surrounding idiopathic stage 4 macular hole contains bundles of actin microfilaments
MENDRINOS E, TSLIMBARI M, TSOKA S, BOCHATON-PILLAT ML, GLODI N, POURNARAS CJ-Genova, Heraklion

462 Mechanics of a macular hole: formation and surgical closure
PEDDADA R, WEINBERG D-Casper, WY, Milwaukee, WI

463 Long-term visual prognosis in necrotising herpetic retinitis

464 Vitreous haemorrhage and retinal vasculitis as manifestations of cat-scratch disease
DORE S, CONTINI E, CARTA P, PINNA A-Sassari

465 Syphilis, return of an old disease?
KRAUT A, VIDOVIC VALENTINIC N-Ljubljana
Why you need to be reading

Acta Ophthalmologica

- **Impact** – our impact factor continues to increase and now stands at 2.138*, placing us amongst the most highly cited ophthalmology journals
- **Coverage that’s relevant to you** – encompassing all aspects of the anatomy, function and diseases of the eye
- **Official publication** of EVER and all five Nordic Ophthalmological Societies

**MEMBERS OF EVER RECEIVE FREE ONLINE ACCESS TO ACTA OPHTHALMOLOGICA**

To make sure *Acta Ophthalmologica* is part of your collection, or to submit an article visit: www.actaophthalmologica.com

---

FOR SIGHT:
The Future of Eye and Vision Research
May 2–6 • Fort Lauderdale, Florida

Abstract submission: October 15–December 4, 2009
www.arvo.org/am
EVER 2009 programme
EVER 2009 programme

LEROY BP: 3422
LEVEZIEL N: 4313
LIANG F: 342, 2267
LIBONDI T: 245, 2447, 3313
LIM L: 253
LIU C: 4121
LDEFFLER KU: 4361
LÖFGREN S: 3442
LOPEZ-GIL N: 2435
LOTTER AJ: 2341
LOU M: 3141, 3443
MACKENSEN F: 4545
MACKEY D: 2346
MAIER M: 426, 3113, 3317
MAICON L: 4315
MAIKOHUL D: 4135
MAKHOUL M: 402, 4357
MANGIORIS G: 333
MANKOWSKI W: 3321
MANTOVANI A: 4456
MARANGONI D: 4416
MARIANOVIC B: 425, 3316
MARQUEZ-NEVEU C: 223, 224, 2454, 2455
MARTIN L: 220, 2255
MASZAMBIA N: 4314
MATTER JM: 2141
MAYER CF: 429, 2418
MCNAUGHT A: 2466
MENCUCI R: 411, 2436
MENDRONIS E: 267, 461
MICHAEL R: 316, 3245
MIDELFART A: 2261
MIDENA E: 1364
MIHELIC M: 3324
MILANO G: 231
MILAZZO S: 2363
MILKA M: 309, 2275, 3338
MÖLLER HU: 3861
MÖNNESTAM E: 336
MONTAVON F: 218
MONTERO MORENO JA: 403, 2412, 4358
MOROIMORUSI B: 2365
MULFORD C: 4143
MUJT M: 458, 4217
MURAINE M: 3434
NEPP J: 304, 3138, 3334
NERI P: 1219, 121, 4156
NICOLLS S: 2271
NISCHAL KK: 2361
NOCHEZ Y: 340, 349, 3267
NOVAK ANDREJCSS K: 350
NOWINSKA A: 314, 2243, 2277
NUBLE M: 3322
NUNES S: 4212
OBRADOVA IG: 3143
OLAFSDOTTIR OB: 2464
OLESEN H: 2276
OLDERSHON EM: 3444
O'NEILL-BIBA M: 3124
ORGUEL S: 4415
OSBORNE NW: 3222
PADICK T: 3326
PAHOR D: 430
PAULER A: 254
PALADINI I: 3134
PALLIKARIS IG: 2153
PAPAS G: 3414
PAQUES M: 2311
PARRIZZANI R: 4164
PATEL S: 454
PEARCE L: 451
PEDDADA R: 462
PEDROSSO DOMELLOF F: 2231
PEDROTTI E: 3321
PEER J: 4363
PEMP B: 2434
PENTARI I: 307, 3336
PEREZ VS: 4324
PEREZ CARRASCO MJ: 431
PEREZ GARCIA D: 325, 354
PELLEMI I: 3222
PESCE G: 328
PETROVSKY G: 4332
PHILIPPAI E: 360
PIELIVAT L: 2451
PINELLO L: 256
PINILLI A: 217, 446
PINNA A: 249
PISHELLA P: 2431
PLANT G: 1231
PLEYER U: 1211, 3464, 4253
POCOBELLA A: 2273
POGORZALEK N: 418
POPOSKI V: 3314
POURNARAS CA: 1251, 1343, 2462, 4113, 4413
PRASANNA G: 2323
PRAUSE JU: 1366, 2472
PRIETO CALVO E: 263, 460
PRODOCHIMO G: 4227
PUELL MC: 356
PUK D: 4142
RABENSTEINER DF: 207
RADECKA L: 420
RAMIREZ AI: 211
RAMIREZ JM: 213
RAINBARD M: 433
RAUSCHER F: 359, 3123
REXAK M: 2414
REITSAMER HA: 244, 2421, 2446
RESERDE AP: 2125
RITTER T: 3462
RIVA CE: 2375
ROCHA DE SOUSA A: 265
ROMANOVSKY EG: 4255
ROUX M: 4144
ROZEMA J: 3244, 4133
RUNGE CW: 288
RUSKOV A: 4166
SANCHEZ RAMOS C: 357, 422
SAW SM: 3225
SAIYEH RR: 320
SCHALENBURG A: 4168
SCHIRRA F: 2334
SCHMIDTERER L: 2155, 2231, 2354, 4411
SCHMIDT D: 4252
SCHOLL HP: 2342
SCHOLLMAYER P: 415
SEGUE CRESPO MM: 364, 365
SERGARC S: 1365, 2374
SERRA U: 4354
SEETH S: 243, 352, 2148, 3262
SENTROUK E: 2415
SHAMSHINNOVA AM: 369
SHEN T: 2171
SIMON E: 272
SIOSTRAND Z J: 447
SKOTTMAN H: 2132
SMITH ND: 3353
SNEAD M: 3211
SÖDERBERG PG: 3441, 4311
SPIESS W: 2373, 3421
STALMANS I: 2156, 3151, 3451
STANARO C: 4264
STANOJLOVIC S: 329
STEFANOTTOU M: 3416
STEHOUWER M: 2213
STEVENS AM: 3354
STOIBER J: 4126
STOJANOVIC N: 229, 255
STRASSER T: 370
STRATOS A: 317
STROHMAYER C: 269
STRUBLE CB: 259, 2426
STUNJ S: 412
SURJANO M: 3155
TALONI M: 4425
TASSIGNON M: 3272
TEKAVIC POMPE M: 3121
TEMPRANO J: 4225, 4326
TENGXU KAMALDEN TA: 214
THERMO K: 2325
THURET G: 3433
TODANI A: 225, 2456
TRANOS P: 3415
TRIVINO A: 212
TSIKA C: 432, 2223
TSULIMBARIS M: 4334
TSOKA P: 4331
TUGAL-TUTKUN I: 4151
TURKO CE: 427, 2416
URRI A: 2133
VALYI Z: 324, 326
VAN AKEN E: 3215
VAN BERGEN T: 2442, 4134
VAN CALSTER J: 4231
VAN DEN BIER T: 3241
VAN DE VERSE S: 2441, 4232
VANDEWALLE E: 3152, 4233
VAN GINDERDEUREN R: 3153, 4162
VAN MARLE G: 209
VARSANYI B: 368
VASILEVA P: 2476
VELIKAY-PAREL M: 3115
VERBRAAK FD: 2111, 2212
VERONESE RODRIGUES ML: 239, 2445
VIDOVIC VALENTINIC N: 414
VIIRI J: 216, 271
VILLARELUL E: 343, 345
VOIGT M: 1253
VON HOLSTEIN SL: 3265
VORONKOVA E: 2458
WACKERNAGEL W: 348, 3266
WEGENER A: 3144, 4241
WEGER M: 2143
WILLERMANN E: 212, 2235
WOOD T: 3131

PRESENTING FIRST AUTHORS
EVER wishes everyone of its past and present sponsors good future for the coming years and thanks especially the following companies, many of which are our long-term supporters, for their generous sponsorship. Thanks to their support EVER can continue to encourage research and dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.
Thank you sponsors

Exhibitors

Welcome reception

Media sponsors

EVER 2009 programme
ABOUT THE PROGRAMME BOOK

This programme book is organised chronologically

Four digit numbers refer to oral presentations

\[ \text{Day} \mid \text{Timeslot} \mid \text{Hall} \mid \text{Order in session} \]

Three digit numbers refer to posters

\[ \text{Day} \mid \text{Order in the postersession} \]

The sessions are colour-coded

- Special Interest Symposium (SIS)
- Keynote Lecture
- Workshop
- Free Papers (FP)
- General Assembly & Business Meeting
- Poster Session
- Joint Meeting
- Course
- Social
- Commercial Interest Symposium (CIS)

FP = Free Paper session
SIS = Special Interest Symposium
CIS = Commercial Interest Symposium
\( \bigcirc \) = EVER travel grant recipient
\( \bigcirc \) = EVER listed countries travel grant recipient
\( \bigcirc \) = Alta Eficacia Tecnología SL, Spain, travel grant recipient
r\( f \) = Rapid Fire presentation

Scientific sections

- ACB = Anatomy/Cell Biology
- COS = Cornea/Ocular Surface
- G = Glaucoma
- IM = Immunology/Microbiology
- LC = Lens and Cataract
- MBGE = Molecular Biology/Genetics/Epidemiology
- NSPH = Neuro-ophthalmology/Strabismology/Paediatric Ophthalmology/History of Ophthalmology
- PBP = Physiology/Biochemistry/Pharmacology
- PO = Pathology/Oncology
- RV = Retina/Vitreous
- VEP = Vision Sciences/Electrophysiology/Physiological Optics
Call for Course and SIS 2010

Proposals for courses and SIS are welcome online from November 20, 2009 on. The deadline for submission of outlines is January 20, 2010 through the EVER website. Submissions must be discussed with the Section Programme Secretary.